Influenza
Conditions
Keywords
GSK Bio's influenza vaccine GSK2340274A, influenza infection, GSK Bio's influenza vaccine GSK2340273A
Brief summary
The purpose of this study is to characterize the safety and immunogenicity of the H1N1 (swine) flu vaccines GSK2340273A and GSK2340274A in adults 18 years of age or older. This protocol posting has been updated for sections impacted by the Protocol amendment 1, Sept 2009.
Detailed description
Collaborators: United States Department of Health and Human Services, Office of Biomedical Advanced Research and Development Authority
Interventions
BIOLOGICALGSK2340274A
one or two intramuscular injections
BIOLOGICALGSK2340273A
one or two intramuscular injections
BIOLOGICALSaline placebo
One injection
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Subjects who the investigator believes can and will comply with the requirements of the protocol. * Written informed consent obtained from the subject. * Male and female adults, \>= 18 years of age at the time of the first vaccination. * Safety laboratory test results within the parameters specified in the protocol. * Satisfactory baseline medical assessment by history and physical examination. * Comprehension of the study requirements, ability to comprehend and comply with procedures for collection of safety data, expressed availability for the required study period, and ability and willingness to attend scheduled visits as documented by signature on the informed consent document. * Access to a consistent means of telephone contact, which may be either in the home or at the workplace, land line or mobile, but NOT a pay phone or other multiple-user device. * Female subjects of non-childbearing potential may be enrolled in the study. * Female subjects of childbearing potential may be enrolled in the study, if the subject: * has practiced adequate contraception for 30 days prior to vaccination, and * has a negative pregnancy test on the day of first vaccination, and * has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series.
Exclusion criteria
* Medical history of physician-confirmed infection with an A/California/7/2009 (H1N1)v-like virus * Previous vaccination at any time with an H1N1v-like virus vaccine or a medical history of physician-confirmed infection with an H1N1v-like virus. * Presence of evidence of substance abuse or of neurological or psychiatric diagnoses which, even if stable, are deemed by the investigator to render the potential subject unable/unlikely to provide accurate safety reports. * Presence of a temperature \>= 38.0ºC (\>=100.4ºF), or acute symptoms greater than mild severity on the scheduled date of first vaccination. * Diagnosed with cancer, or treatment for cancer, within 3 years. * Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required). * Receipt of systemic glucocorticoids within 1 month prior to study enrollment, or any other cytotoxic or immunosuppressive drug within 6 months of study enrollment. Topical, intra-articularly injected, or inhaled glucocorticoids, topical calcineurin inhibitors or imiquimod are allowed. * Receipt of any immunoglobulins and/or any blood products within 3 months of study enrollment or planned administration of any of these products during the study period. * Any significant disorder of coagulation or treatment with warfarin derivatives or heparin. Persons receiving individual doses of low molecular weight heparin outside of 24 hours prior to vaccination, are eligible. Persons receiving prophylactic antiplatelet medications, e.g., low-dose acetylsalicylic acid, and without a clinically-apparent bleeding tendency, are eligible. * An acute evolving neurological disorder or history of Guillain-Barré syndrome within 6 weeks of receipt of seasonal influenza vaccine * With the exception of seasonal influenza vaccination, administration of any vaccine(s) within 30 days before study vaccination on Day 0. Seasonal influenza vaccine may be administered up to 14 days prior to study vaccination on Day 0. * Planned administration of any vaccine not foreseen by the study protocol between Day 0 and the Day 42 phlebotomy, including seasonal influenza vaccine or a monovalent pandemic H1N1 vaccine other than the study vaccines. * Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine/product, or planned use during the study period. * Any known or suspected allergy to any constituent of influenza vaccines; a history of anaphylactic-type reaction to any constituent of influenza vaccines; or a history of severe adverse reaction to a previous influenza vaccine. * Known pregnancy or a positive urine beta-human chorionic gonadotropin test result prior to the first vaccination. * Lactating or nursing women.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Subjects Seropositive for Haemagglutination Inhibition (HI) Antibodies Against the A/California Virus Strain | At Day 0 | A seropositive subject against the A/California/ virus strain was defined as a subject with H1N1 reciprocal haemagglutination inhibition (HI) antibody titers greater than or equal to (≥) the seropositivity cut-off of 1:10. Results were tabulated according to age strata: subjects between 18 to 60 years (y) old and subjects older than (\>) 60 years. |
| Number of Subjects Seropositive for (HI) Antibodies Against the A/California Virus Strain | At Day 0 | A seropositive subject against the A/California/ virus strain was defined as a subject with H1N1 reciprocal haemagglutination inhibition (HI) antibody titers greater than or equal to (≥) the seropositivity cut-off of 1:10. Results were tabulated according to age strata: subjects between 18 to 64 years (y) old and subjects \> 64 years. |
| Number of Seroconverted (SCR) Subjects for Haemagglutination Inhibition (HI) Antibodies Against A/California Virus Strain | At Day 21 | A seroconverted subject was defined as a vaccinated subject who had a post-vaccination titer ≥ 1:40 and at least a 4-fold increase in pre-vaccination titer. The Flu strain assessed was A/California/7/09 (H1N1)v-like) and results were tabulated for subjects between 18 and 60 years of age and older (\>60y). |
| Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Strain | At Day 21 | A seroconverted subject was defined as a vaccinated subject who had a post-vaccination titer ≥ 1:40 and at least a 4-fold increase in pre-vaccination titer. The Flu strain assessed was A/California/7/09 (H1N1)v-like) and results were tabulated for subjects between 18 and 64 years and older (\>64y). |
| Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | At Day 0 | A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40. The Flu strain assessed was A/California/7/2009 (H1N1)v-like (Flu A/CAL/7/09) and results were tabulated for subjects between 18 and 60 years and older (\>60y). |
| Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | At Day 0 | A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40. The Flu strain assessed was Flu A/CAL/7/09 and results were tabulated for subjects between 18 and 64 years and older (\>64y). |
| Seroconversion Factor (SCF) for Haemagglutination Inhibition (HI) Antibodies Against A/California Virus Strain | At Day 21 | SCF was defined as the fold increase in serum HI geometric mean ratio (mean\[log10(POST/PRE)\]) vaccination compared to Day 21. The flu strain assessed was Flu A/CAL/7/09 and results were tabulated for subjects between 18 and 60 years of age and older (\>60y). |
| Seroconversion Factor (SCF) for HI Antibodies Against A/California Strain | At Day 21 | SCF was defined as the fold increase in serum HI geometric mean ratio (mean\[log10(POST/PRE)\]) vaccination compared to Day 21. The flu strain assessed was Flu A/CAL/7/09 and results were tabulated for subjects between 18 and 64 years of age and older (\>64y). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Seroconverted (SCR) Subjects for HI Antibodies | At Day 182 | A seroconverted subject was defined as a vaccinated subject who had a post-vaccination titer ≥ 1:40 and at least a 4-fold increase in pre-vaccination titer. The Flu strain assessed was A/California/7/09 (H1N1)v-like) and results were tabulated for subjects between 18-60 years of age and older (\>60y) and for subjects between 18-64 years old and \>64 years. |
| Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | At Days 0 and 182 | A seroprotected subject was defined as a vaccinated subject with serum HI antibody titers ≥ 1:40. The Flu strain assessed was A/California/7/09 (H1N1)v-like) and results were tabulated for subjects between 18-60 years of age and older (\>60y) and for subjects between 18-64 years old and \>64 years. |
| Adjusted Geometric Mean Titer (GMT) Ratios of A/California Virus Strain | At Day 21 | Titers were presented as geometric mean titers (GMTs). Adjusted GMT was defined as the geometric mean antibody titer adjusted for Previous Vaccination baseline titers and results were tabulated for subjects between 18-60 years, \> 60 years, 18-64 years and \> 64 years, from the pooled group GSK2340274A F1 and GSK2340273A F3\_2D Group. |
| Adjusted Geometric Mean Titer (GMT) Ratios of A/California Strain | At Day 21 | Titers were presented as geometric mean titers (GMTs). Adjusted GMT was defined as the geometric mean antibody titer adjusted for Previous Vaccination baseline titers and results were tabulated for subjects between 18-60 years, \> 60 years, 18-64 years and \> 64 years, from the pooled groups GSK2340274A F1 and GSK2340273A F2. |
| Adjusted GMT Ratios of A/California Virus Strain | At Day 21 | Titers were presented as geometric mean titers (GMTs). Adjusted GMT was defined as the geometric mean antibody titer adjusted for Previous Vaccination baseline titers and results were tabulated for subjects between 18-60 years, \> 60 years, 18-64 years and \> 64 years, from the pooled group GSK2340274A F1 and the GSK2340273A F1\_1D Group. |
| Adjusted GMT Ratios of A/California Strain | At Day 21 | Titers were presented as geometric mean titers (GMTs). Adjusted GMT was defined as the geometric mean antibody titer adjusted for Previous Vaccination baseline titers and results were tabulated for subjects between 18-60 years, \> 60 years, 18-64 years and \> 64 years, from the pooled group GSK2340274A F2 and the GSK2340273A F3\_2D Group. |
| Adjusted GMT Ratios for A/California Virus Strain | At Day 21 | Titers were presented as geometric mean titers (GMTs). Adjusted GMT was defined as the geometric mean antibody titer adjusted for Previous Vaccination baseline titers and results were tabulated for subjects between 18-60 years, \> 60 years, 18-64 years and \> 64 years, from the pooled groups GSK2340274A F2 and GSK2340273A F2. |
| Adjusted GMT Ratios for A/California Strain | At Day 21 | Titers were presented as geometric mean titers (GMTs). Adjusted GMT was defined as the geometric mean antibody titer adjusted for Previous Vaccination baseline titers and results were tabulated for subjects between 18-60 years, \> 60 years, 18-64 years and \> 64 years, from the pooled group GSK2340274A F2 and the GSK2340273A F1\_1D Group. |
| Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | At Days 0 and 21 | A seropositive subject against the A/California/ virus strain was defined as a subject with H1N1 reciprocal haemagglutination inhibition (HI) antibody titers greater than or equal to (≥) the seropositivity cut-off of 1:10. Results were tabulated according to age strata: subjects between 18 to 60 years (y) old and \> 60 years and subjects between 18 and 64 years old and \> 64 years, respectively. |
| Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | During the 7-day (Day 0-6) post-vaccination period following each dose and across doses, for subjects between 18-64 years of age | Assessed solicited general symptoms were fatigue, fever \[defined as axillary temperature equal to or above (≥) 38 degrees Celsius (°C)\], headache, joint pain at other location, muscle aches, shivering and sweating. Any = occurrence of the symptom regardless of intensity grade or relationship to vaccination. Grade 3 symptom = symptom that prevented normal everyday activities as assessed by inability to attend/do work or school, or required intervention of a physician/healthcare provider. Grade 3 fever = fever ≥ 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination. |
| Number of Subjects With Any and Grade 3 Solicited General Symptoms | During the 7-day (Days 0-6) post-Dose 3 vaccination period, for subjects > 60 years of age | Assessed solicited general symptoms were fatigue, fever \[defined as axillary temperature equal to or above (≥) 38 degrees Celsius (°C)\], headache, joint pain at other location, muscle aches, shivering and sweating. Any = occurrence of the symptom regardless of intensity grade or relationship to vaccination. Grade 3 symptom = symptom that prevented normal everyday activities as assessed by inability to attend/do work or school, or required intervention of a physician/healthcare provider. Grade 3 fever = fever ≥ 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination. Results were tabulated for subjects in GSK2340273A F2\_1D Group, who were older than 60 years of age (\>60y). |
| Number of Subjects With Abnormal Biochemical and Haematological Levels | At Days 7, 21, 28, 42 and 182, for subjects between 18-64 years of age | Among biochemical and haematological parameters assessed were alanine aminotransferase \[ALT\], alkaline phosphatase \[AP\], aspartate aminotransferase \[AST\], basophils \[BAS\], bilirubin \[BIL\], bilirubin conjugated/direct \[BIL/CD\] creatinine \[CREA\], eosinophils \[EOS\], hematocrit \[HEM\], haemoglobin \[Hgb\], lymphocytes \[LYM\], monocytes \[MON\], neutrophils \[NEU\], platelets \[PLA\], red blood cells \[RBC\], blood urea nitrogen \[BUN\] and white blood cells \[WBC\]. Levels of haematological/biochemical parameters assessed in terms of normal laboratory values were - unknown, below, within and above the reference range defined for the specified time point and laboratory parameter. |
| Number of Subjects With Any Medically-attended Adverse Events (MAEs) | Days 0 to 385 | MAEs were defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any was defined as the occurrence of any MAE regardless of intensity grade or relation to vaccination. Results were tabulated for subjects aged between 18 and 64 years and older (\>64y). |
| Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) | Days 0 to 365 | Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Results were tabulated for subjects aged between 18-64 years and above 65 years (+65y). |
| Number of Subjects With Any Unsolicited Adverse Events (AEs) | Within the 42-day (Days 0-41) post-vaccination period | An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. |
| Number of Subjects With Serious Adverse Events (SAEs) | During the entire study period (from Day 0 to Day 385) | Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Results were tabulated for subjects aged between 18-64 years and older (\>64y). |
| Number of Subjects With Any and Grade 3 Solicited Local Symptoms | During the 7-day (Days 0-6) post-vaccination period following each dose and across doses, for subjects between 18-64 years of age | Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activities as assessed by inability to attend/do work or school. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. |
| Titers for HI Antibodies Against A/California Strain | At Days 0 and 21 | Antibody titers were presented as geometric mean titers (GMTs), for the seropositivity cut-off of 1:10. Results were tabulated according to age strata: subjects between 18 to 60 years (y) old and \> 60 years and subjects between 18 and 64 years old and \> 64 years, respectively. |
| Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | At Day 21 | A seroconverted subject was defined as a vaccinated subject who had a post-vaccination titer ≥ 1:40 and at least a 4-fold increase in pre-vaccination titer. The Flu strain assessed was A/California/7/09 (H1N1)v-like) and results were tabulated for subjects between 18-60 years of age and older (\>60y) and for subjects between 18-64 years old and \>64 years. |
| Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | At Days 0 and 21 | A seroprotected subject was defined as a vaccinated subject with serum HI antibody titers ≥ 1:40. The Flu strain assessed was A/California/7/09 (H1N1)v-like) and results were tabulated for subjects between 18-60 years of age and older (\>60y) and for subjects between 18-64 years old and \>64 years. |
| Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | At Day 21 | SCF was defined as the fold increase in serum HI geometric mean ratio (mean\[log10(POST/PRE)\]) vaccination compared to Day 21. The flu strain assessed was Flu A/CAL/7/09 and results were tabulated for subjects between 18-60 years of age and older (\> 60y) and for subjects between 18-64 years old and \> 64 years. |
| Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | At Days 0 and 42 | A seropositive subject against the A/California/ virus strain was defined as a subject with H1N1 reciprocal HI antibody titers greater than or equal to (≥) the seropositivity cut-off of 1:10. Results were tabulated according to age strata: subjects between 18 to 60 years (y) old and \> 60 years and subjects between 18 and 64 years old and \> 64 years, respectively. |
| Titers for HI Antibodies Against the A/California Virus Strain | At Days 0 and 42 | Antibody titers were presented as geometric mean titers (GMTs), for the seropositivity cut-off of 1:10. Results were tabulated according to age strata: subjects between 18 to 60 years (y) old and \> 60 years and subjects between 18 and 64 years old and \> 64 years, respectively. |
| Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | At Days 0 and 42 | A seroprotected subject was defined as a vaccinated subject with serum HI antibody titers ≥ 1:40. The Flu strain assessed was A/California/7/09 (H1N1)v-like) and results were tabulated for subjects between 18-60 years of age and older (\>60y) and for subjects between 18-64 years old and \>64 years. |
Countries
Canada, United States
Participant flow
Pre-assignment details
Out of 1343 subjects enrolled in the study, 3 subjects did not receive any vaccination.
Participants by arm
| Arm | Count |
|---|---|
| GSK2340274A F1_2D Group Healthy male or female subjects, above and including 18 years of age, who received 2 doses of Formulation 1 (F1) of GSK2340274A vaccine: at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and at Day 21, administered intramuscularly into the deltoid region of the dominant arm. | 222 |
| GSK2340274A F2_2D Group Healthy male or female subjects, above and including 18 years of age, who received 2 doses of Formulation 2 (F2) of GSK2340274A vaccine: at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and at Day 21, administered intramuscularly into the deltoid region of the dominant arm. | 114 |
| GSK2340274A F2_1D Group Healthy male or female subjects, above and including 18 years of age, who received one dose of Formulation 2 (F2) of GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and one dose of saline placebo at Day 21, administered intramuscularly into the deltoid region of the dominant arm. | 112 |
| GSK2340274A F1_1D Group Healthy male or female subjects, above and including 18 years of age, who received one dose of Formulation 1 (F1) of GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and one dose of saline placebo at Day 21, administered intramuscularly into the deltoid region of the dominant arm. | 221 |
| GSK2340273A F1_1D Group Healthy male or female subjects, above and including 18 years of age, who received one dose of Formulation 1 (F1) of GSK2340273A vaccine at Day 0, administrated intramuscularly into the deltoid region of the non-dominant arm and one dose of saline at Day 21, administered intramuscularly into the deltoid region of the dominant arm. | 223 |
| GSK2340273A F2_2D Group Healthy male or female subjects, above and including 18 years of age, who received 2 doses of Formulation 2 (F2) of GSK2340273A vaccine: at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and at Day 21, administered intramuscularly into the deltoid region of the dominant arm. | 115 |
| GSK2340273A F2_1D Group Healthy male or female subjects, above and including 18 years of age, who received one dose of Formulation 2 (F2) of GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and one dose of saline at Day 21, administered intramuscularly into the deltoid region of the dominant arm. Subjects above (\>) 60 years old received an additional dose of Formulation 2 (F2) of GSK2340273A vaccine after Day 42, administered into the deltoid region of the non-dominant arm. | 111 |
| GSK2340273A F3_2D Group Healthy male or female subjects, above and including 18 years of age, who received 2 doses of Formulation 3 of GSK2340273A vaccine: at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and at Day 21, administered intramuscularly into the deltoid region of the dominant arm. | 222 |
| Total | 1,340 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 |
|---|---|---|---|---|---|---|---|---|---|
| Overall Study | Adverse Event | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Overall Study | Lost to Follow-up | 6 | 1 | 2 | 6 | 6 | 5 | 3 | 2 |
| Overall Study | Migrated/moved from study area | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Overall Study | Serious Adverse Event | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Overall Study | Withdrawal by Subject | 4 | 0 | 0 | 1 | 3 | 2 | 1 | 2 |
Baseline characteristics
| Characteristic | GSK2340274A F1_2D Group | GSK2340274A F2_2D Group | GSK2340274A F2_1D Group | GSK2340274A F1_1D Group | GSK2340273A F1_1D Group | GSK2340273A F2_2D Group | GSK2340273A F2_1D Group | GSK2340273A F3_2D Group | Total |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | 58.4 Years STANDARD_DEVIATION 17.37 | 58.8 Years STANDARD_DEVIATION 18.69 | 59.3 Years STANDARD_DEVIATION 17.71 | 58.6 Years STANDARD_DEVIATION 17.91 | 58.7 Years STANDARD_DEVIATION 17.59 | 58.4 Years STANDARD_DEVIATION 17.96 | 58.8 Years STANDARD_DEVIATION 17.55 | 58.7 Years STANDARD_DEVIATION 18.16 | 58.7 Years STANDARD_DEVIATION 17.8 |
| Race/Ethnicity, Customized Geographic ancestry African heritage/ African American | 14 Participants | 7 Participants | 7 Participants | 14 Participants | 9 Participants | 8 Participants | 4 Participants | 12 Participants | 75 Participants |
| Race/Ethnicity, Customized Geographic ancestry American Indian or Alaskan Native | 0 Participants | 0 Participants | 0 Participants | 2 Participants | 1 Participants | 1 Participants | 0 Participants | 0 Participants | 4 Participants |
| Race/Ethnicity, Customized Geographic ancestry Asian - Central/South Asian heritage | 0 Participants | 1 Participants | 0 Participants | 2 Participants | 1 Participants | 1 Participants | 1 Participants | 3 Participants | 9 Participants |
| Race/Ethnicity, Customized Geographic ancestry Asian - East Asian heritage | 0 Participants | 2 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants | 0 Participants | 2 Participants | 6 Participants |
| Race/Ethnicity, Customized Geographic ancestry Asian - Japanese heritage | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 3 Participants |
| Race/Ethnicity, Customized Geographic ancestry Asian - South East Asian heritage | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants | 1 Participants | 0 Participants | 2 Participants | 5 Participants |
| Race/Ethnicity, Customized Geographic ancestry Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Geographic ancestry Other | 3 Participants | 1 Participants | 2 Participants | 9 Participants | 10 Participants | 2 Participants | 3 Participants | 5 Participants | 35 Participants |
| Race/Ethnicity, Customized Geographic ancestry White - Arabic/North African heritage | 3 Participants | 1 Participants | 1 Participants | 0 Participants | 1 Participants | 3 Participants | 1 Participants | 1 Participants | 11 Participants |
| Race/Ethnicity, Customized Geographic ancestry White - Caucasian/European heritage | 201 Participants | 102 Participants | 101 Participants | 192 Participants | 199 Participants | 98 Participants | 102 Participants | 196 Participants | 1191 Participants |
| Sex: Female, Male Female | 135 Participants | 69 Participants | 69 Participants | 138 Participants | 132 Participants | 70 Participants | 75 Participants | 128 Participants | 816 Participants |
| Sex: Female, Male Male | 87 Participants | 45 Participants | 43 Participants | 83 Participants | 91 Participants | 45 Participants | 36 Participants | 94 Participants | 524 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk |
|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 1 / 222 | 1 / 114 | 0 / 112 | 0 / 221 | 0 / 223 | 0 / 115 | 0 / 111 | 1 / 222 |
| other Total, other adverse events | 189 / 222 | 86 / 114 | 79 / 112 | 188 / 221 | 126 / 223 | 74 / 115 | 76 / 111 | 130 / 222 |
| serious Total, serious adverse events | 19 / 222 | 5 / 114 | 6 / 112 | 8 / 221 | 8 / 223 | 5 / 115 | 9 / 111 | 11 / 222 |
Outcome results
Primary
Number of Seroconverted (SCR) Subjects for Haemagglutination Inhibition (HI) Antibodies Against A/California Virus Strain
A seroconverted subject was defined as a vaccinated subject who had a post-vaccination titer ≥ 1:40 and at least a 4-fold increase in pre-vaccination titer. The Flu strain assessed was A/California/7/09 (H1N1)v-like) and results were tabulated for subjects between 18 and 60 years of age and older (\>60y).
Time frame: At Day 21
Population: The analysis was performed only on subjects receiving F1 or F2 of GSK2340274A vaccine from the ATP cohort for immunogenicity, which included all subjects who received the vaccine/placebo doses on both Days 0 and 21 and for whom assay results for antibodies against A/California-like HA antigen for blood samples taken were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK2340274A F1_2D Group | Number of Seroconverted (SCR) Subjects for Haemagglutination Inhibition (HI) Antibodies Against A/California Virus Strain | 18 - 60y | 149 Participants |
| GSK2340274A F1_2D Group | Number of Seroconverted (SCR) Subjects for Haemagglutination Inhibition (HI) Antibodies Against A/California Virus Strain | > 60y | 215 Participants |
| GSK2340274A F2_2D Group | Number of Seroconverted (SCR) Subjects for Haemagglutination Inhibition (HI) Antibodies Against A/California Virus Strain | 18 - 60y | 69 Participants |
| GSK2340274A F2_2D Group | Number of Seroconverted (SCR) Subjects for Haemagglutination Inhibition (HI) Antibodies Against A/California Virus Strain | > 60y | 82 Participants |
Primary
Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Strain
A seroconverted subject was defined as a vaccinated subject who had a post-vaccination titer ≥ 1:40 and at least a 4-fold increase in pre-vaccination titer. The Flu strain assessed was A/California/7/09 (H1N1)v-like) and results were tabulated for subjects between 18 and 64 years and older (\>64y).
Time frame: At Day 21
Population: The analysis was performed only on subjects receiving F1 or F2 of GSK2340274A vaccine from the ATP cohort for immunogenicity, which included all subjects who received the vaccine/placebo doses on both Days 0 and 21 and for whom assay results for antibodies against A/California-like HA antigen for blood samples taken were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK2340274A F1_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Strain | 18 - 64y | 163 Participants |
| GSK2340274A F1_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Strain | > 64y | 201 Participants |
| GSK2340274A F2_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Strain | 18 - 64y | 75 Participants |
| GSK2340274A F2_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Strain | > 64y | 76 Participants |
Primary
Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain
A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40. The Flu strain assessed was Flu A/CAL/7/09 and results were tabulated for subjects between 18 and 64 years and older (\>64y).
Time frame: At Day 21
Population: The analysis was performed only on subjects receiving F1 or F2 of GSK2340274A vaccine from the ATP cohort for immunogenicity, which included all subjects who received the vaccine/placebo doses on both Days 0 and 21 and for whom assay results for antibodies against A/California-like HA antigen for blood samples taken were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK2340274A F1_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | 18 - 64y | 176 Participants |
| GSK2340274A F1_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | > 64y | 234 Participants |
| GSK2340274A F2_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | 18 - 64y | 86 Participants |
| GSK2340274A F2_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | > 64y | 96 Participants |
Primary
Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain
A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40. The Flu strain assessed was Flu A/CAL/7/09 and results were tabulated for subjects between 18 and 64 years and older (\>64y).
Time frame: At Day 0
Population: The analysis was performed only on subjects receiving F1 or F2 of GSK2340274A vaccine from the ATP cohort for immunogenicity, which included all subjects who received the vaccine/placebo doses on both Days 0 and 21 and for whom assay results for antibodies against A/California-like HA antigen for blood samples taken were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK2340274A F1_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | 18 - 64y | 36 Participants |
| GSK2340274A F1_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | > 64y | 34 Participants |
| GSK2340274A F2_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | 18 - 64y | 19 Participants |
| GSK2340274A F2_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | > 64y | 20 Participants |
Primary
Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain
A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40. The Flu strain assessed was A/California/7/2009 (H1N1)v-like (Flu A/CAL/7/09) and results were tabulated for subjects between 18 and 60 years and older (\>60y).
Time frame: At Day 0
Population: The analysis was performed only on subjects receiving F1 or F2 of GSK2340274A vaccine from the ATP cohort for immunogenicity, which included all subjects who received the vaccine/placebo doses on both Days 0 and 21 and for whom assay results for antibodies against A/California-like HA antigen for blood samples taken were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK2340274A F1_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | 18 - 60y | 35 Participants |
| GSK2340274A F1_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | > 60y | 35 Participants |
| GSK2340274A F2_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | 18 - 60y | 17 Participants |
| GSK2340274A F2_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | > 60y | 22 Participants |
Primary
Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain
A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40. The Flu strain assessed was Flu A/CAL/7/09 and results were tabulated for subjects between 18 and 60 years and older (\>60y).
Time frame: At Day 21
Population: The analysis was performed only on subjects receiving F1 or F2 of GSK2340274A vaccine from the ATP cohort for immunogenicity, which included all subjects who received the vaccine/placebo doses on both Days 0 and 21 and for whom assay results for antibodies against A/California-like HA antigen for blood samples taken were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK2340274A F1_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | 18 - 60y | 160 Participants |
| GSK2340274A F1_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | > 60y | 250 Participants |
| GSK2340274A F2_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | 18 - 60y | 78 Participants |
| GSK2340274A F2_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | > 60y | 104 Participants |
Primary
Number of Subjects Seropositive for Haemagglutination Inhibition (HI) Antibodies Against the A/California Virus Strain
A seropositive subject against the A/California/ virus strain was defined as a subject with H1N1 reciprocal haemagglutination inhibition (HI) antibody titers greater than or equal to (≥) the seropositivity cut-off of 1:10. Results were tabulated according to age strata: subjects between 18 to 60 years (y) old and subjects older than (\>) 60 years.
Time frame: At Day 0
Population: The analysis was performed only on subjects receiving F1 or F2 of GSK2340274A vaccine from the According-to-Protocol (ATP) cohort for immunogenicity, which included all subjects who received the vaccine/placebo doses on Days 0, 21 and for whom assay results for antibodies against A/California-like HA antigen for blood samples taken were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK2340274A F1_2D Group | Number of Subjects Seropositive for Haemagglutination Inhibition (HI) Antibodies Against the A/California Virus Strain | 18 - 60y | 91 Participants |
| GSK2340274A F1_2D Group | Number of Subjects Seropositive for Haemagglutination Inhibition (HI) Antibodies Against the A/California Virus Strain | > 60y | 168 Participants |
| GSK2340274A F2_2D Group | Number of Subjects Seropositive for Haemagglutination Inhibition (HI) Antibodies Against the A/California Virus Strain | 18 - 60y | 48 Participants |
| GSK2340274A F2_2D Group | Number of Subjects Seropositive for Haemagglutination Inhibition (HI) Antibodies Against the A/California Virus Strain | > 60y | 75 Participants |
Primary
Number of Subjects Seropositive for Haemagglutination Inhibition (HI) Antibodies Against the A/California Virus Strain
A seropositive subject against the A/California/ virus strain was defined as a subject with H1N1 reciprocal haemagglutination inhibition (HI) antibody titers greater than or equal to (≥) the seropositivity cut-off of 1:10. Results were tabulated according to age strata: subjects between 18 to 60 years (y) old and subjects \> 60 years.
Time frame: At Day 21
Population: The analysis was performed only on subjects receiving F1 or F2 of GSK2340274A vaccine from the ATP cohort for immunogenicity, which included all subjects who received the vaccine/placebo doses on both Days 0 and 21 and for whom assay results for antibodies against A/California-like HA antigen for blood samples taken were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK2340274A F1_2D Group | Number of Subjects Seropositive for Haemagglutination Inhibition (HI) Antibodies Against the A/California Virus Strain | 18 - 60y | 163 Participants |
| GSK2340274A F1_2D Group | Number of Subjects Seropositive for Haemagglutination Inhibition (HI) Antibodies Against the A/California Virus Strain | > 60y | 275 Participants |
| GSK2340274A F2_2D Group | Number of Subjects Seropositive for Haemagglutination Inhibition (HI) Antibodies Against the A/California Virus Strain | 18 - 60y | 83 Participants |
| GSK2340274A F2_2D Group | Number of Subjects Seropositive for Haemagglutination Inhibition (HI) Antibodies Against the A/California Virus Strain | > 60y | 136 Participants |
Primary
Number of Subjects Seropositive for (HI) Antibodies Against the A/California Virus Strain
A seropositive subject against the A/California/ virus strain was defined as a subject with H1N1 reciprocal haemagglutination inhibition (HI) antibody titers greater than or equal to (≥) the seropositivity cut-off of 1:10. Results were tabulated according to age strata: subjects between 18 to 64 years (y) old and subjects \> 64 years.
Time frame: At Day 0
Population: The analysis was performed only on subjects receiving F1 or F2 of GSK2340274A vaccine from the ATP cohort for immunogenicity, which included all subjects who received the vaccine/placebo doses on both Days 0 and 21 and for whom assay results for antibodies against A/California-like HA antigen for blood samples taken were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK2340274A F1_2D Group | Number of Subjects Seropositive for (HI) Antibodies Against the A/California Virus Strain | 18 - 64y | 99 Participants |
| GSK2340274A F1_2D Group | Number of Subjects Seropositive for (HI) Antibodies Against the A/California Virus Strain | > 64y | 160 Participants |
| GSK2340274A F2_2D Group | Number of Subjects Seropositive for (HI) Antibodies Against the A/California Virus Strain | 18 - 64y | 52 Participants |
| GSK2340274A F2_2D Group | Number of Subjects Seropositive for (HI) Antibodies Against the A/California Virus Strain | > 64y | 71 Participants |
Primary
Number of Subjects Seropositive for (HI) Antibodies Against the A/California Virus Strain
A seropositive subject against the A/California/ virus strain was defined as a subject with H1N1 reciprocal haemagglutination inhibition (HI) antibody titers greater than or equal to (≥) the seropositivity cut-off of 1:10. Results were tabulated according to age strata: subjects between 18 to 64 years (y) old and subjects \> 64 years.
Time frame: At Day 21
Population: The analysis was performed only on subjects receiving F1 or F2 of GSK2340274A vaccine from the ATP cohort for immunogenicity, which included all subjects who received the vaccine/placebo doses on both Days 0 and 21 and for whom assay results for antibodies against A/California-like HA antigen for blood samples taken were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK2340274A F1_2D Group | Number of Subjects Seropositive for (HI) Antibodies Against the A/California Virus Strain | 18 - 64y | 181 Participants |
| GSK2340274A F1_2D Group | Number of Subjects Seropositive for (HI) Antibodies Against the A/California Virus Strain | > 64y | 257 Participants |
| GSK2340274A F2_2D Group | Number of Subjects Seropositive for (HI) Antibodies Against the A/California Virus Strain | 18 - 64y | 93 Participants |
| GSK2340274A F2_2D Group | Number of Subjects Seropositive for (HI) Antibodies Against the A/California Virus Strain | > 64y | 126 Participants |
Primary
Seroconversion Factor (SCF) for Haemagglutination Inhibition (HI) Antibodies Against A/California Virus Strain
SCF was defined as the fold increase in serum HI geometric mean ratio (mean\[log10(POST/PRE)\]) vaccination compared to Day 21. The flu strain assessed was Flu A/CAL/7/09 and results were tabulated for subjects between 18 and 60 years of age and older (\>60y).
Time frame: At Day 21
Population: The analysis was performed only on subjects receiving F1 or F2 of GSK2340274A vaccine from the ATP cohort for immunogenicity, which included all subjects who received the vaccine/placebo doses on both Days 0 and 21 and for whom assay results for antibodies against A/California-like HA antigen for blood samples taken were available.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK2340274A F1_2D Group | Seroconversion Factor (SCF) for Haemagglutination Inhibition (HI) Antibodies Against A/California Virus Strain | 18 - 60y | 30.1 Fold increase |
| GSK2340274A F1_2D Group | Seroconversion Factor (SCF) for Haemagglutination Inhibition (HI) Antibodies Against A/California Virus Strain | > 60y | 10.8 Fold increase |
| GSK2340274A F2_2D Group | Seroconversion Factor (SCF) for Haemagglutination Inhibition (HI) Antibodies Against A/California Virus Strain | 18 - 60y | 18.5 Fold increase |
| GSK2340274A F2_2D Group | Seroconversion Factor (SCF) for Haemagglutination Inhibition (HI) Antibodies Against A/California Virus Strain | > 60y | 7.4 Fold increase |
Primary
Seroconversion Factor (SCF) for HI Antibodies Against A/California Strain
SCF was defined as the fold increase in serum HI geometric mean ratio (mean\[log10(POST/PRE)\]) vaccination compared to Day 21. The flu strain assessed was Flu A/CAL/7/09 and results were tabulated for subjects between 18 and 64 years of age and older (\>64y).
Time frame: At Day 21
Population: The analysis was performed only on subjects receiving F1 or F2 of GSK2340274A vaccine from the ATP cohort for immunogenicity, which included all subjects who received the vaccine/placebo doses on both Days 0 and 21 and for whom assay results for antibodies against A/California-like HA antigen for blood samples taken were available.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK2340274A F1_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Strain | 18 - 64y | 29.2 Fold increase |
| GSK2340274A F1_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Strain | > 64y | 10.3 Fold increase |
| GSK2340274A F2_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Strain | 18 - 64y | 17.0 Fold increase |
| GSK2340274A F2_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Strain | > 64y | 7.3 Fold increase |
Secondary
Adjusted Geometric Mean Titer (GMT) Ratios of A/California Strain
Titers were presented as geometric mean titers (GMTs). Adjusted GMT was defined as the geometric mean antibody titer adjusted for Previous Vaccination baseline titers and results were tabulated for subjects between 18-60 years, \> 60 years, 18-64 years and \> 64 years, from the pooled groups GSK2340274A F1 and GSK2340273A F2.
Time frame: At Day 21
Population: The analysis was performed on the ATP cohort for immunogenicity,which included all subjects who received the vaccine/placebo doses on Days 0 and 21 and for whom assay results for antibodies against vaccine antigen for blood samples taken were available. This analysis focused on subjects receiving GSK2340274A F1 vaccine versus GSK2340273A F2 vaccine
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| GSK2340274A F1_2D Group | Adjusted Geometric Mean Titer (GMT) Ratios of A/California Strain | Adjusted A/California ratio, 18-60y | 400.8 Titer |
| GSK2340274A F1_2D Group | Adjusted Geometric Mean Titer (GMT) Ratios of A/California Strain | Adjusted A/California ratio, > 60y | 162.3 Titer |
| GSK2340274A F1_2D Group | Adjusted Geometric Mean Titer (GMT) Ratios of A/California Strain | Adjusted A/California ratio, 18-64y | 385.7 Titer |
| GSK2340274A F1_2D Group | Adjusted Geometric Mean Titer (GMT) Ratios of A/California Strain | Adjusted A/California ratio, > 64y | 159.2 Titer |
| GSK2340274A F2_2D Group | Adjusted Geometric Mean Titer (GMT) Ratios of A/California Strain | Adjusted A/California ratio, > 64y | 56.8 Titer |
| GSK2340274A F2_2D Group | Adjusted Geometric Mean Titer (GMT) Ratios of A/California Strain | Adjusted A/California ratio, 18-60y | 215.3 Titer |
| GSK2340274A F2_2D Group | Adjusted Geometric Mean Titer (GMT) Ratios of A/California Strain | Adjusted A/California ratio, 18-64y | 220.2 Titer |
| GSK2340274A F2_2D Group | Adjusted Geometric Mean Titer (GMT) Ratios of A/California Strain | Adjusted A/California ratio, > 60y | 61.4 Titer |
Secondary
Adjusted Geometric Mean Titer (GMT) Ratios of A/California Virus Strain
Titers were presented as geometric mean titers (GMTs). Adjusted GMT was defined as the geometric mean antibody titer adjusted for Previous Vaccination baseline titers and results were tabulated for subjects between 18-60 years, \> 60 years, 18-64 years and \> 64 years, from the pooled group GSK2340274A F1 and GSK2340273A F3\_2D Group.
Time frame: At Day 21
Population: The analysis was performed on the ATP cohort for immunogenicity,which included all subjects who received the vaccine/placebo doses on Days 0 and 21 and for whom assay results for antibodies against vaccine antigen for blood samples taken were available. This analysis focused on subjects receiving GSK2340274A F1 vaccine versus GSK2340273A F3 vaccine
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| GSK2340274A F1_2D Group | Adjusted Geometric Mean Titer (GMT) Ratios of A/California Virus Strain | Adjusted A/California ratio, 18-64y | 381.7 Titers |
| GSK2340274A F1_2D Group | Adjusted Geometric Mean Titer (GMT) Ratios of A/California Virus Strain | Adjusted A/California ratio, 18-60y | 404.9 Titers |
| GSK2340274A F1_2D Group | Adjusted Geometric Mean Titer (GMT) Ratios of A/California Virus Strain | Adjusted A/California ratio, > 64y | 156.0 Titers |
| GSK2340274A F1_2D Group | Adjusted Geometric Mean Titer (GMT) Ratios of A/California Virus Strain | Adjusted A/California ratio, > 60y | 152.7 Titers |
| GSK2340274A F2_2D Group | Adjusted Geometric Mean Titer (GMT) Ratios of A/California Virus Strain | Adjusted A/California ratio, > 64y | 56.2 Titers |
| GSK2340274A F2_2D Group | Adjusted Geometric Mean Titer (GMT) Ratios of A/California Virus Strain | Adjusted A/California ratio, 18-64y | 101.6 Titers |
| GSK2340274A F2_2D Group | Adjusted Geometric Mean Titer (GMT) Ratios of A/California Virus Strain | Adjusted A/California ratio, > 60y | 55.0 Titers |
| GSK2340274A F2_2D Group | Adjusted Geometric Mean Titer (GMT) Ratios of A/California Virus Strain | Adjusted A/California ratio, 18-60y | 104.5 Titers |
Secondary
Adjusted GMT Ratios for A/California Strain
Titers were presented as geometric mean titers (GMTs). Adjusted GMT was defined as the geometric mean antibody titer adjusted for Previous Vaccination baseline titers and results were tabulated for subjects between 18-60 years, \> 60 years, 18-64 years and \> 64 years, from the pooled group GSK2340274A F2 and the GSK2340273A F1\_1D Group.
Time frame: At Day 21
Population: The analysis was performed on the ATP cohort for immunogenicity,which included all subjects who received the vaccine/placebo doses on Days 0 and 21 and for whom assay results for antibodies against vaccine antigen for blood samples taken were available. This analysis focused on subjects receiving GSK2340274A F2 vaccine vs. GSK2340273A F1\_1D vaccine
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| GSK2340274A F1_2D Group | Adjusted GMT Ratios for A/California Strain | Adjusted A/California ratio, > 60y | 129.6 Titer |
| GSK2340274A F1_2D Group | Adjusted GMT Ratios for A/California Strain | Adjusted A/California ratio, 18-64y | 221.8 Titer |
| GSK2340274A F1_2D Group | Adjusted GMT Ratios for A/California Strain | Adjusted A/California ratio, 18-60y | 246.4 Titer |
| GSK2340274A F1_2D Group | Adjusted GMT Ratios for A/California Strain | Adjusted A/California ratio, > 64y | 130.7 Titer |
| GSK2340274A F2_2D Group | Adjusted GMT Ratios for A/California Strain | Adjusted A/California ratio, > 64y | 106.3 Titer |
| GSK2340274A F2_2D Group | Adjusted GMT Ratios for A/California Strain | Adjusted A/California ratio, > 60y | 110.2 Titer |
| GSK2340274A F2_2D Group | Adjusted GMT Ratios for A/California Strain | Adjusted A/California ratio, 18-60y | 150.9 Titer |
| GSK2340274A F2_2D Group | Adjusted GMT Ratios for A/California Strain | Adjusted A/California ratio, 18-64y | 150.4 Titer |
Secondary
Adjusted GMT Ratios for A/California Virus Strain
Titers were presented as geometric mean titers (GMTs). Adjusted GMT was defined as the geometric mean antibody titer adjusted for Previous Vaccination baseline titers and results were tabulated for subjects between 18-60 years, \> 60 years, 18-64 years and \> 64 years, from the pooled groups GSK2340274A F2 and GSK2340273A F2.
Time frame: At Day 21
Population: The analysis was performed on the ATP cohort for immunogenicity,which included all subjects who received the vaccine/placebo doses on Days 0 and 21 and for whom assay results for antibodies against vaccine antigen for blood samples taken were available. This analysis focused on subjects receiving GSK2340274A F2 vaccine versus GSK2340273A F2 vaccine
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| GSK2340274A F1_2D Group | Adjusted GMT Ratios for A/California Virus Strain | Adjusted A/California ratio, 18-60y | 234.3 Titer |
| GSK2340274A F1_2D Group | Adjusted GMT Ratios for A/California Virus Strain | Adjusted A/California ratio, > 60y | 119.9 Titer |
| GSK2340274A F1_2D Group | Adjusted GMT Ratios for A/California Virus Strain | Adjusted A/California ratio, 18-64y | 213.7 Titer |
| GSK2340274A F1_2D Group | Adjusted GMT Ratios for A/California Virus Strain | Adjusted A/California ratio, > 64y | 118.2 Titer |
| GSK2340274A F2_2D Group | Adjusted GMT Ratios for A/California Virus Strain | Adjusted A/California ratio, > 64y | 61.6 Titer |
| GSK2340274A F2_2D Group | Adjusted GMT Ratios for A/California Virus Strain | Adjusted A/California ratio, 18-60y | 208.6 Titer |
| GSK2340274A F2_2D Group | Adjusted GMT Ratios for A/California Virus Strain | Adjusted A/California ratio, 18-64y | 216.7 Titer |
| GSK2340274A F2_2D Group | Adjusted GMT Ratios for A/California Virus Strain | Adjusted A/California ratio, > 60y | 68.3 Titer |
Secondary
Adjusted GMT Ratios of A/California Strain
Titers were presented as geometric mean titers (GMTs). Adjusted GMT was defined as the geometric mean antibody titer adjusted for Previous Vaccination baseline titers and results were tabulated for subjects between 18-60 years, \> 60 years, 18-64 years and \> 64 years, from the pooled group GSK2340274A F2 and the GSK2340273A F3\_2D Group.
Time frame: At Day 21
Population: The analysis was performed on the ATP cohort for immunogenicity,which included all subjects who received the vaccine/placebo doses on Days 0 and 21 and for whom assay results for antibodies against vaccine antigen for blood samples taken were available. This analysis focused on subjects receiving GSK2340274A F2 vaccine versus GSK2340273A F3 vaccine
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| GSK2340274A F1_2D Group | Adjusted GMT Ratios of A/California Strain | Adjusted A/California ratio, 18-60y | 238.2 Titer |
| GSK2340274A F1_2D Group | Adjusted GMT Ratios of A/California Strain | Adjusted A/California ratio, > 60y | 113.3 Titer |
| GSK2340274A F1_2D Group | Adjusted GMT Ratios of A/California Strain | Adjusted A/California ratio, 18-64y | 213.9 Titer |
| GSK2340274A F1_2D Group | Adjusted GMT Ratios of A/California Strain | Adjusted A/California ratio, > 64y | 117.2 Titer |
| GSK2340274A F2_2D Group | Adjusted GMT Ratios of A/California Strain | Adjusted A/California ratio, > 64y | 60.5 Titer |
| GSK2340274A F2_2D Group | Adjusted GMT Ratios of A/California Strain | Adjusted A/California ratio, 18-60y | 102.3 Titer |
| GSK2340274A F2_2D Group | Adjusted GMT Ratios of A/California Strain | Adjusted A/California ratio, 18-64y | 99.5 Titer |
| GSK2340274A F2_2D Group | Adjusted GMT Ratios of A/California Strain | Adjusted A/California ratio, > 60y | 61.3 Titer |
Secondary
Adjusted GMT Ratios of A/California Virus Strain
Titers were presented as geometric mean titers (GMTs). Adjusted GMT was defined as the geometric mean antibody titer adjusted for Previous Vaccination baseline titers and results were tabulated for subjects between 18-60 years, \> 60 years, 18-64 years and \> 64 years, from the pooled group GSK2340274A F1 and the GSK2340273A F1\_1D Group.
Time frame: At Day 21
Population: The analysis was performed on the ATP cohort for immunogenicity,which included all subjects who received the vaccine/placebo doses on Days 0 and 21 and for whom assay results for antibodies against vaccine antigen for blood samples taken were available. This analysis focused on subjects receiving GSK2340274A F1 vaccine vs GSK2340273A F1\_1D vaccine
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| GSK2340274A F1_2D Group | Adjusted GMT Ratios of A/California Virus Strain | Adjusted A/California ratio, 18-64y | 393.8 Titer |
| GSK2340274A F1_2D Group | Adjusted GMT Ratios of A/California Virus Strain | Adjusted A/California ratio, 18-60y | 414.8 Titer |
| GSK2340274A F1_2D Group | Adjusted GMT Ratios of A/California Virus Strain | Adjusted A/California ratio, > 64y | 169.9 Titer |
| GSK2340274A F1_2D Group | Adjusted GMT Ratios of A/California Virus Strain | Adjusted A/California ratio, > 60y | 172.9 Titer |
| GSK2340274A F2_2D Group | Adjusted GMT Ratios of A/California Virus Strain | Adjusted A/California ratio, > 64y | 94.2 Titer |
| GSK2340274A F2_2D Group | Adjusted GMT Ratios of A/California Virus Strain | Adjusted A/California ratio, 18-60y | 153.1 Titer |
| GSK2340274A F2_2D Group | Adjusted GMT Ratios of A/California Virus Strain | Adjusted A/California ratio, 18-64y | 151.6 Titer |
| GSK2340274A F2_2D Group | Adjusted GMT Ratios of A/California Virus Strain | Adjusted A/California ratio, > 60y | 95.6 Titer |
Secondary
Number of Seroconverted (SCR) Subjects for HI Antibodies
A seroconverted subject was defined as a vaccinated subject who had a post-vaccination titer ≥ 1:40 and at least a 4-fold increase in pre-vaccination titer. The Flu strain assessed was A/California/7/09 (H1N1)v-like) and results were tabulated for subjects between 18-60 years of age and older (\>60y) and for subjects between 18-64 years old and \>64 years.
Time frame: At Day 182
Population: The analysis was performed on the ATP cohort for immunogenicity, which included all subjects who received the vaccine/ placebo doses on both Days 0 and 21 and from whom assay results for antibodies against A/California-like HA antigen for blood samples taken were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK2340274A F1_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies | A/California strain, 18-64 y | 79 Participants |
| GSK2340274A F1_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies | A/California strain, > 60 y | 93 Participants |
| GSK2340274A F1_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies | A/California strain, > 64 y | 85 Participants |
| GSK2340274A F1_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies | A/California strain, 18-60 y | 71 Participants |
| GSK2340274A F2_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies | A/California strain, 18-64 y | 38 Participants |
| GSK2340274A F2_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies | A/California strain, 18-60 y | 36 Participants |
| GSK2340274A F2_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies | A/California strain, > 60 y | 34 Participants |
| GSK2340274A F2_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies | A/California strain, > 64 y | 32 Participants |
| GSK2340274A F2_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies | A/California strain, 18-64 y | 26 Participants |
| GSK2340274A F2_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies | A/California strain, > 60 y | 16 Participants |
| GSK2340274A F2_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies | A/California strain, 18-60 y | 26 Participants |
| GSK2340274A F2_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies | A/California strain, > 64 y | 16 Participants |
| GSK2340274A F1_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies | A/California strain, > 64 y | 53 Participants |
| GSK2340274A F1_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies | A/California strain, > 60 y | 55 Participants |
| GSK2340274A F1_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies | A/California strain, 18-60 y | 57 Participants |
| GSK2340274A F1_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies | A/California strain, 18-64 y | 59 Participants |
| GSK2340273A F1_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies | A/California strain, 18-64 y | 50 Participants |
| GSK2340273A F1_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies | A/California strain, > 60 y | 52 Participants |
| GSK2340273A F1_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies | A/California strain, > 64 y | 46 Participants |
| GSK2340273A F1_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies | A/California strain, 18-60 y | 44 Participants |
| GSK2340273A F2_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies | A/California strain, 18-60 y | 29 Participants |
| GSK2340273A F2_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies | A/California strain, > 60 y | 25 Participants |
| GSK2340273A F2_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies | A/California strain, 18-64 y | 31 Participants |
| GSK2340273A F2_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies | A/California strain, > 64 y | 23 Participants |
| GSK2340273A F2_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies | A/California strain, 18-64 y | 32 Participants |
| GSK2340273A F2_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies | A/California strain, > 64 y | 17 Participants |
| GSK2340273A F2_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies | A/California strain, 18-60 y | 28 Participants |
| GSK2340273A F2_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies | A/California strain, > 60 y | 21 Participants |
| GSK2340273A F3_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies | A/California strain, 18-64 y | 46 Participants |
| GSK2340273A F3_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies | A/California strain, > 60 y | 40 Participants |
| GSK2340273A F3_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies | A/California strain, > 64 y | 39 Participants |
| GSK2340273A F3_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies | A/California strain, 18-60 y | 45 Participants |
Secondary
Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain
A seroconverted subject was defined as a vaccinated subject who had a post-vaccination titer ≥ 1:40 and at least a 4-fold increase in pre-vaccination titer. The Flu strain assessed was A/California/7/09 (H1N1)v-like) and results were tabulated for subjects between 18-60 years of age and older (\>60y) and for subjects between 18-64 years old and \>64 years.
Time frame: At Day 42
Population: The analysis was performed on the ATP cohort for immunogenicity, which included all subjects who received the vaccine/ placebo doses on both Days 0 and 21 and from whom assay results for antibodies against A/California-like HA antigen for blood samples taken were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK2340274A F1_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, 18-60 y | 36 Participants |
| GSK2340274A F1_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, > 64 y | 52 Participants |
| GSK2340274A F1_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, > 60 y | 54 Participants |
| GSK2340274A F1_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, 18-64 y | 38 Participants |
| GSK2340274A F2_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, 18-60 y | 37 Participants |
| GSK2340274A F2_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, 18-64 y | 41 Participants |
| GSK2340274A F2_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, > 64 y | 50 Participants |
| GSK2340274A F2_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, > 60 y | 54 Participants |
| GSK2340274A F2_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, 18-60 y | 31 Participants |
| GSK2340274A F2_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, > 60 y | 37 Participants |
| GSK2340274A F2_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, 18-64 y | 33 Participants |
| GSK2340274A F2_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, > 64 y | 35 Participants |
| GSK2340274A F1_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, 18-60 y | 37 Participants |
| GSK2340274A F1_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, 18-64 y | 39 Participants |
| GSK2340274A F1_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, > 64 y | 48 Participants |
| GSK2340274A F1_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, > 60 y | 50 Participants |
| GSK2340273A F1_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, 18-64 y | 23 Participants |
| GSK2340273A F1_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, > 64 y | 36 Participants |
| GSK2340273A F1_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, 18-60 y | 21 Participants |
| GSK2340273A F1_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, > 60 y | 38 Participants |
| GSK2340273A F2_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, 18-64 y | 40 Participants |
| GSK2340273A F2_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, 18-60 y | 38 Participants |
| GSK2340273A F2_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, > 64 y | 28 Participants |
| GSK2340273A F2_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, > 60 y | 30 Participants |
| GSK2340273A F2_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, > 64 y | 18 Participants |
| GSK2340273A F2_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, > 60 y | 22 Participants |
| GSK2340273A F2_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, 18-60 y | 32 Participants |
| GSK2340273A F2_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, 18-64 y | 36 Participants |
| GSK2340273A F3_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, 18-60 y | 25 Participants |
| GSK2340273A F3_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, > 64 y | 33 Participants |
| GSK2340273A F3_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, > 60 y | 36 Participants |
| GSK2340273A F3_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, 18-64 y | 28 Participants |
Secondary
Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain
A seroconverted subject was defined as a vaccinated subject who had a post-vaccination titer ≥ 1:40 and at least a 4-fold increase in pre-vaccination titer. The Flu strain assessed was A/California/7/09 (H1N1)v-like) and results were tabulated for subjects between 18-60 years of age and older (\>60y) and for subjects between 18-64 years old and \>64 years.
Time frame: At Day 21
Population: The analysis was performed on the ATP cohort for immunogenicity, which included all subjects who received the vaccine/ placebo doses on both Days 0 and 21 and from whom assay results for antibodies against A/California-like HA antigen for blood samples taken were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK2340274A F1_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, > 64y | 99 Participants |
| GSK2340274A F1_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, 18-64y | 84 Participants |
| GSK2340274A F1_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, > 60y | 109 Participants |
| GSK2340274A F1_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, 18-60y | 74 Participants |
| GSK2340274A F2_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, > 64y | 41 Participants |
| GSK2340274A F2_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, 18-64y | 38 Participants |
| GSK2340274A F2_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, > 60y | 45 Participants |
| GSK2340274A F2_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, 18-60y | 34 Participants |
| GSK2340274A F2_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, 18-60y | 35 Participants |
| GSK2340274A F2_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, > 64y | 35 Participants |
| GSK2340274A F2_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, 18-64y | 37 Participants |
| GSK2340274A F2_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, > 60y | 37 Participants |
| GSK2340274A F1_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, > 64y | 102 Participants |
| GSK2340274A F1_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, 18-60y | 75 Participants |
| GSK2340274A F1_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, > 60y | 106 Participants |
| GSK2340274A F1_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, 18-64y | 79 Participants |
| GSK2340273A F1_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, > 60y | 69 Participants |
| GSK2340273A F1_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, 18-60y | 58 Participants |
| GSK2340273A F1_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, 18-64y | 64 Participants |
| GSK2340273A F1_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, > 64y | 63 Participants |
| GSK2340273A F2_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, > 64y | 22 Participants |
| GSK2340273A F2_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, 18-64y | 37 Participants |
| GSK2340273A F2_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, > 60y | 24 Participants |
| GSK2340273A F2_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, 18-60y | 35 Participants |
| GSK2340273A F2_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, 18-64y | 37 Participants |
| GSK2340273A F2_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, 18-60y | 33 Participants |
| GSK2340273A F2_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, > 64y | 23 Participants |
| GSK2340273A F2_1D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, > 60y | 27 Participants |
| GSK2340273A F3_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, > 64y | 46 Participants |
| GSK2340273A F3_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, 18-60y | 49 Participants |
| GSK2340273A F3_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, > 60y | 52 Participants |
| GSK2340273A F3_2D Group | Number of Seroconverted (SCR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain, 18-64y | 55 Participants |
Secondary
Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain
A seroprotected subject was defined as a vaccinated subject with serum HI antibody titers ≥ 1:40. The Flu strain assessed was A/California/7/09 (H1N1)v-like) and results were tabulated for subjects between 18-60 years of age and older (\>60y) and for subjects between 18-64 years old and \>64 years.
Time frame: At Days 0 and 21
Population: The analysis was performed on the ATP cohort for immunogenicity, which included all subjects who received the vaccine/ placebo doses on both Days 0 and 21 and from whom assay results for antibodies against A/California-like HA antigen for blood samples taken were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK2340274A F1_2D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (> 60y), Day 21 | 127 Participants |
| GSK2340274A F1_2D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (> 60y), Day 0 | 16 Participants |
| GSK2340274A F1_2D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (18-64y), Day 0 | 19 Participants |
| GSK2340274A F1_2D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (> 64y), Day 21 | 115 Participants |
| GSK2340274A F1_2D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (18-60y), Day 0 | 18 Participants |
| GSK2340274A F1_2D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (18-64y), Day 21 | 91 Participants |
| GSK2340274A F1_2D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (> 64y), Day 0 | 15 Participants |
| GSK2340274A F1_2D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (18-60y), Day 21 | 79 Participants |
| GSK2340274A F2_2D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (> 64y), Day 0 | 8 Participants |
| GSK2340274A F2_2D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (18-60y), Day 21 | 40 Participants |
| GSK2340274A F2_2D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (> 60y), Day 0 | 9 Participants |
| GSK2340274A F2_2D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (18-64y), Day 21 | 45 Participants |
| GSK2340274A F2_2D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (> 64y), Day 21 | 50 Participants |
| GSK2340274A F2_2D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (18-64y), Day 0 | 11 Participants |
| GSK2340274A F2_2D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (18-60y), Day 0 | 10 Participants |
| GSK2340274A F2_2D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (> 60y), Day 21 | 55 Participants |
| GSK2340274A F2_1D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (> 64y), Day 0 | 12 Participants |
| GSK2340274A F2_1D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (18-60y), Day 0 | 7 Participants |
| GSK2340274A F2_1D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (18-64y), Day 21 | 41 Participants |
| GSK2340274A F2_1D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (18-60y), Day 21 | 38 Participants |
| GSK2340274A F2_1D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (> 60y), Day 21 | 49 Participants |
| GSK2340274A F2_1D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (> 60y), Day 0 | 13 Participants |
| GSK2340274A F2_1D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (18-64y), Day 0 | 8 Participants |
| GSK2340274A F2_1D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (> 64y), Day 21 | 46 Participants |
| GSK2340274A F1_1D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (> 64y), Day 0 | 19 Participants |
| GSK2340274A F1_1D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (18-60y), Day 0 | 17 Participants |
| GSK2340274A F1_1D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (18-64y), Day 0 | 17 Participants |
| GSK2340274A F1_1D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (18-60y), Day 21 | 81 Participants |
| GSK2340274A F1_1D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (> 60y), Day 0 | 19 Participants |
| GSK2340274A F1_1D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (18-64y), Day 21 | 85 Participants |
| GSK2340274A F1_1D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (> 60y), Day 21 | 123 Participants |
| GSK2340274A F1_1D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (> 64y), Day 21 | 119 Participants |
| GSK2340273A F1_1D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (> 60y), Day 0 | 23 Participants |
| GSK2340273A F1_1D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (18-60y), Day 21 | 71 Participants |
| GSK2340273A F1_1D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (18-64y), Day 21 | 79 Participants |
| GSK2340273A F1_1D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (18-60y), Day 0 | 19 Participants |
| GSK2340273A F1_1D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (> 60y), Day 21 | 93 Participants |
| GSK2340273A F1_1D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (> 64y), Day 0 | 22 Participants |
| GSK2340273A F1_1D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (18-64y), Day 0 | 20 Participants |
| GSK2340273A F1_1D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (> 64y), Day 21 | 85 Participants |
| GSK2340273A F2_2D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (18-64y), Day 21 | 41 Participants |
| GSK2340273A F2_2D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (> 64y), Day 0 | 6 Participants |
| GSK2340273A F2_2D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (18-60y), Day 21 | 39 Participants |
| GSK2340273A F2_2D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (> 60y), Day 21 | 32 Participants |
| GSK2340273A F2_2D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (> 60y), Day 0 | 7 Participants |
| GSK2340273A F2_2D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (18-60y), Day 0 | 7 Participants |
| GSK2340273A F2_2D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (> 64y), Day 21 | 30 Participants |
| GSK2340273A F2_2D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (18-64y), Day 0 | 8 Participants |
| GSK2340273A F2_1D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (18-64y), Day 21 | 45 Participants |
| GSK2340273A F2_1D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (> 64y), Day 21 | 35 Participants |
| GSK2340273A F2_1D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (18-60y), Day 21 | 41 Participants |
| GSK2340273A F2_1D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (> 60y), Day 21 | 39 Participants |
| GSK2340273A F2_1D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (> 64y), Day 0 | 11 Participants |
| GSK2340273A F2_1D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (18-64y), Day 0 | 7 Participants |
| GSK2340273A F2_1D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (18-60y), Day 0 | 6 Participants |
| GSK2340273A F2_1D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (> 60y), Day 0 | 12 Participants |
| GSK2340273A F3_2D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (18-60y), Day 21 | 61 Participants |
| GSK2340273A F3_2D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (> 64y), Day 0 | 17 Participants |
| GSK2340273A F3_2D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (18-64y), Day 21 | 68 Participants |
| GSK2340273A F3_2D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (> 60y), Day 0 | 18 Participants |
| GSK2340273A F3_2D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (18-64y), Day 0 | 14 Participants |
| GSK2340273A F3_2D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (18-60y), Day 0 | 13 Participants |
| GSK2340273A F3_2D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (> 60y), Day 21 | 74 Participants |
| GSK2340273A F3_2D Group | Number of Seroprotected (SPR) Subjects Against HI Antibodies for the A/California Virus Strain | A/California strain (> 64y), Day 21 | 67 Participants |
Secondary
Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain
A seroprotected subject was defined as a vaccinated subject with serum HI antibody titers ≥ 1:40. The Flu strain assessed was A/California/7/09 (H1N1)v-like) and results were tabulated for subjects between 18-60 years of age and older (\>60y) and for subjects between 18-64 years old and \>64 years.
Time frame: At Days 0 and 42
Population: The analysis was performed on the ATP cohort for immunogenicity, which included all subjects who received the vaccine/ placebo doses on both Days 0 and 21 and from whom assay results for antibodies against A/California-like HA antigen for blood samples taken were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK2340274A F1_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (18-60 y), Day 0 | 10 Participants |
| GSK2340274A F1_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (18-64 y), Day 42 | 42 Participants |
| GSK2340274A F1_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (> 64 y), Day 42 | 59 Participants |
| GSK2340274A F1_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (18-64 y), Day 0 | 10 Participants |
| GSK2340274A F1_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (> 60 y), Day 0 | 3 Participants |
| GSK2340274A F1_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (> 64 y), Day 0 | 3 Participants |
| GSK2340274A F1_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (18-60 y), Day 42 | 39 Participants |
| GSK2340274A F1_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (> 60 y), Day 42 | 62 Participants |
| GSK2340274A F2_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (18-60 y), Day 0 | 9 Participants |
| GSK2340274A F2_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (18-64 y), Day 42 | 44 Participants |
| GSK2340274A F2_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (18-64 y), Day 0 | 10 Participants |
| GSK2340274A F2_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (18-60 y), Day 42 | 39 Participants |
| GSK2340274A F2_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (> 64 y), Day 42 | 55 Participants |
| GSK2340274A F2_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (> 64 y), Day 0 | 8 Participants |
| GSK2340274A F2_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (> 60 y), Day 0 | 9 Participants |
| GSK2340274A F2_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (> 60 y), Day 42 | 60 Participants |
| GSK2340274A F2_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (> 64 y), Day 0 | 12 Participants |
| GSK2340274A F2_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (18-60 y), Day 0 | 6 Participants |
| GSK2340274A F2_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (> 64 y), Day 42 | 47 Participants |
| GSK2340274A F2_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (> 60 y), Day 42 | 50 Participants |
| GSK2340274A F2_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (18-60 y), Day 42 | 35 Participants |
| GSK2340274A F2_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (> 60 y), Day 0 | 13 Participants |
| GSK2340274A F2_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (18-64 y), Day 0 | 7 Participants |
| GSK2340274A F2_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (18-64 y), Day 42 | 38 Participants |
| GSK2340274A F1_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (> 60 y), Day 0 | 11 Participants |
| GSK2340274A F1_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (> 64 y), Day 42 | 56 Participants |
| GSK2340274A F1_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (> 60 y), Day 42 | 58 Participants |
| GSK2340274A F1_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (18-64 y), Day 0 | 9 Participants |
| GSK2340274A F1_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (18-60 y), Day 42 | 38 Participants |
| GSK2340274A F1_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (18-64 y), Day 42 | 40 Participants |
| GSK2340274A F1_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (18-60 y), Day 0 | 9 Participants |
| GSK2340274A F1_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (> 64 y), Day 0 | 11 Participants |
| GSK2340273A F1_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (18-60 y), Day 0 | 9 Participants |
| GSK2340273A F1_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (> 64 y), Day 0 | 10 Participants |
| GSK2340273A F1_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (> 60 y), Day 0 | 11 Participants |
| GSK2340273A F1_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (18-64 y), Day 0 | 10 Participants |
| GSK2340273A F1_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (18-60 y), Day 42 | 32 Participants |
| GSK2340273A F1_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (> 64 y), Day 42 | 43 Participants |
| GSK2340273A F1_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (> 60 y), Day 42 | 46 Participants |
| GSK2340273A F1_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (18-64 y), Day 42 | 35 Participants |
| GSK2340273A F2_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (> 64 y), Day 0 | 6 Participants |
| GSK2340273A F2_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (> 60 y), Day 0 | 7 Participants |
| GSK2340273A F2_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (18-64 y), Day 0 | 8 Participants |
| GSK2340273A F2_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (18-60 y), Day 0 | 7 Participants |
| GSK2340273A F2_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (18-60 y), Day 42 | 42 Participants |
| GSK2340273A F2_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (> 60 y), Day 42 | 39 Participants |
| GSK2340273A F2_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (18-64 y), Day 42 | 44 Participants |
| GSK2340273A F2_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (> 64 y), Day 42 | 37 Participants |
| GSK2340273A F2_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (> 60 y), Day 42 | 36 Participants |
| GSK2340273A F2_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (> 64 y), Day 42 | 32 Participants |
| GSK2340273A F2_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (18-64 y), Day 42 | 44 Participants |
| GSK2340273A F2_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (18-60 y), Day 42 | 40 Participants |
| GSK2340273A F2_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (18-60 y), Day 0 | 6 Participants |
| GSK2340273A F2_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (> 64 y), Day 0 | 11 Participants |
| GSK2340273A F2_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (> 60 y), Day 0 | 12 Participants |
| GSK2340273A F2_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (18-64 y), Day 0 | 7 Participants |
| GSK2340273A F3_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (> 64 y), Day 42 | 40 Participants |
| GSK2340273A F3_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (> 64 y), Day 0 | 6 Participants |
| GSK2340273A F3_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (18-64 y), Day 0 | 5 Participants |
| GSK2340273A F3_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (18-64 y), Day 42 | 34 Participants |
| GSK2340273A F3_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (18-60 y), Day 42 | 30 Participants |
| GSK2340273A F3_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (> 60 y), Day 0 | 7 Participants |
| GSK2340273A F3_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (18-60 y), Day 0 | 4 Participants |
| GSK2340273A F3_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Strain | A/California (> 60 y), Day 42 | 44 Participants |
Secondary
Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain
A seroprotected subject was defined as a vaccinated subject with serum HI antibody titers ≥ 1:40. The Flu strain assessed was A/California/7/09 (H1N1)v-like) and results were tabulated for subjects between 18-60 years of age and older (\>60y) and for subjects between 18-64 years old and \>64 years.
Time frame: At Days 0 and 182
Population: The analysis was performed on the ATP cohort for immunogenicity, which included all subjects who received the vaccine/ placebo doses on both Days 0 and 21 and from whom assay results for antibodies against A/California-like HA antigen for blood samples taken were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK2340274A F1_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (18-60 y), Day 0 | 18 Participants |
| GSK2340274A F1_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (18-64 y), Day 0 | 19 Participants |
| GSK2340274A F1_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (> 60 y), Day 182 | 109 Participants |
| GSK2340274A F1_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (> 64 y), Day 182 | 99 Participants |
| GSK2340274A F1_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (18-60 y), Day 182 | 75 Participants |
| GSK2340274A F1_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (> 60 y), Day 0 | 15 Participants |
| GSK2340274A F1_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (18-64 y), Day 182 | 85 Participants |
| GSK2340274A F1_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (> 64 y), Day 0 | 14 Participants |
| GSK2340274A F2_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (> 60 y), Day 182 | 44 Participants |
| GSK2340274A F2_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (> 64 y), Day 0 | 8 Participants |
| GSK2340274A F2_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (> 60 y), Day 0 | 9 Participants |
| GSK2340274A F2_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (18-64 y), Day 0 | 11 Participants |
| GSK2340274A F2_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (18-60 y), Day 0 | 10 Participants |
| GSK2340274A F2_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (18-64 y), Day 182 | 42 Participants |
| GSK2340274A F2_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (18-60 y), Day 182 | 39 Participants |
| GSK2340274A F2_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (> 64 y), Day 182 | 41 Participants |
| GSK2340274A F2_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (18-60 y), Day 182 | 33 Participants |
| GSK2340274A F2_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (18-60 y), Day 0 | 7 Participants |
| GSK2340274A F2_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (> 60 y), Day 182 | 32 Participants |
| GSK2340274A F2_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (> 64 y), Day 182 | 31 Participants |
| GSK2340274A F2_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (18-64 y), Day 182 | 34 Participants |
| GSK2340274A F2_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (18-64 y), Day 0 | 8 Participants |
| GSK2340274A F2_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (> 60 y), Day 0 | 13 Participants |
| GSK2340274A F2_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (> 64 y), Day 0 | 12 Participants |
| GSK2340274A F1_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (18-64 y), Day 182 | 72 Participants |
| GSK2340274A F1_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (> 60 y), Day 0 | 18 Participants |
| GSK2340274A F1_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (18-64 y), Day 0 | 17 Participants |
| GSK2340274A F1_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (> 60 y), Day 182 | 85 Participants |
| GSK2340274A F1_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (18-60 y), Day 0 | 17 Participants |
| GSK2340274A F1_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (> 64 y), Day 0 | 18 Participants |
| GSK2340274A F1_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (18-60 y), Day 182 | 70 Participants |
| GSK2340274A F1_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (> 64 y), Day 182 | 83 Participants |
| GSK2340273A F1_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (> 60 y), Day 0 | 23 Participants |
| GSK2340273A F1_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (18-64 y), Day 0 | 18 Participants |
| GSK2340273A F1_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (18-64 y), Day 182 | 65 Participants |
| GSK2340273A F1_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (> 60 y), Day 182 | 75 Participants |
| GSK2340273A F1_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (18-60 y), Day 0 | 17 Participants |
| GSK2340273A F1_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (> 64 y), Day 182 | 68 Participants |
| GSK2340273A F1_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (> 64 y), Day 0 | 22 Participants |
| GSK2340273A F1_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (18-60 y), Day 182 | 58 Participants |
| GSK2340273A F2_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (> 60 y), Day 0 | 7 Participants |
| GSK2340273A F2_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (18-64 y), Day 0 | 7 Participants |
| GSK2340273A F2_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (18-64 y), Day 182 | 37 Participants |
| GSK2340273A F2_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (> 64 y), Day 0 | 6 Participants |
| GSK2340273A F2_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (> 64 y), Day 182 | 29 Participants |
| GSK2340273A F2_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (18-60 y), Day 0 | 6 Participants |
| GSK2340273A F2_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (18-60 y), Day 182 | 35 Participants |
| GSK2340273A F2_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (> 60 y), Day 182 | 31 Participants |
| GSK2340273A F2_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (> 64 y), Day 0 | 11 Participants |
| GSK2340273A F2_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (> 60 y), Day 182 | 33 Participants |
| GSK2340273A F2_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (18-64 y), Day 182 | 37 Participants |
| GSK2340273A F2_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (> 60 y), Day 0 | 12 Participants |
| GSK2340273A F2_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (> 64 y), Day 182 | 29 Participants |
| GSK2340273A F2_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (18-64 y), Day 0 | 7 Participants |
| GSK2340273A F2_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (18-60 y), Day 182 | 33 Participants |
| GSK2340273A F2_1D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (18-60 y), Day 0 | 6 Participants |
| GSK2340273A F3_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (> 64 y), Day 182 | 65 Participants |
| GSK2340273A F3_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (18-64 y), Day 182 | 61 Participants |
| GSK2340273A F3_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (18-64 y), Day 0 | 13 Participants |
| GSK2340273A F3_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (> 60 y), Day 0 | 18 Participants |
| GSK2340273A F3_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (> 64 y), Day 0 | 17 Participants |
| GSK2340273A F3_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (> 60 y), Day 182 | 69 Participants |
| GSK2340273A F3_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (18-60 y), Day 182 | 57 Participants |
| GSK2340273A F3_2D Group | Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain | A/California strain (18-60 y), Day 0 | 12 Participants |
Secondary
Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs)
Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Results were tabulated for subjects aged between 18-64 years and above 65 years (+65y).
Time frame: Days 0 to 365
Population: The analysis was performed on the Total Vaccinated cohort, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK2340274A F1_2D Group | Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) | Any pIMDs, 18-64y | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) | Any pIMDs, + 65y | 2 Participants |
| GSK2340274A F2_2D Group | Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) | Any pIMDs, 18-64y | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) | Any pIMDs, + 65y | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) | Any pIMDs, 18-64y | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) | Any pIMDs, + 65y | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) | Any pIMDs, 18-64y | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) | Any pIMDs, + 65y | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) | Any pIMDs, 18-64y | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) | Any pIMDs, + 65y | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) | Any pIMDs, 18-64y | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) | Any pIMDs, + 65y | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) | Any pIMDs, + 65y | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) | Any pIMDs, 18-64y | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) | Any pIMDs, 18-64y | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) | Any pIMDs, + 65y | 0 Participants |
Secondary
Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain
A seropositive subject against the A/California/ virus strain was defined as a subject with H1N1 reciprocal haemagglutination inhibition (HI) antibody titers greater than or equal to (≥) the seropositivity cut-off of 1:10. Results were tabulated according to age strata: subjects between 18 to 60 years (y) old and \> 60 years and subjects between 18 and 64 years old and \> 64 years, respectively.
Time frame: At Days 0 and 21
Population: The analysis was performed on the ATP cohort for immunogenicity, which included all subjects who received the vaccine/ placebo doses on both Days 0 and 21 and from whom assay results for antibodies against A/California-like HA antigen for blood samples taken were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK2340274A F1_2D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (18-60 y), Day 21 | 80 Participants |
| GSK2340274A F1_2D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (>64 y), Day 21 | 128 Participants |
| GSK2340274A F1_2D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (>64 y), Day 0 | 84 Participants |
| GSK2340274A F1_2D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (18-64 y), Day 0 | 55 Participants |
| GSK2340274A F1_2D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (>60 y), Day 21 | 140 Participants |
| GSK2340274A F1_2D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (18-60 y), Day 0 | 47 Participants |
| GSK2340274A F1_2D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (>60 y), Day 0 | 92 Participants |
| GSK2340274A F1_2D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (18-64 y), Day 21 | 92 Participants |
| GSK2340274A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (>64 y), Day 21 | 63 Participants |
| GSK2340274A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (>60 y), Day 21 | 68 Participants |
| GSK2340274A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (18-60 y), Day 0 | 25 Participants |
| GSK2340274A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (>64 y), Day 0 | 33 Participants |
| GSK2340274A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (18-60 y), Day 21 | 41 Participants |
| GSK2340274A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (18-64 y), Day 21 | 46 Participants |
| GSK2340274A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (18-64 y), Day 0 | 28 Participants |
| GSK2340274A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (>60 y), Day 0 | 36 Participants |
| GSK2340274A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (18-64 y), Day 21 | 47 Participants |
| GSK2340274A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (>60 y), Day 21 | 68 Participants |
| GSK2340274A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (18-60 y), Day 0 | 23 Participants |
| GSK2340274A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (18-64 y), Day 0 | 24 Participants |
| GSK2340274A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (>64 y), Day 0 | 38 Participants |
| GSK2340274A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (>64 y), Day 21 | 63 Participants |
| GSK2340274A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (>60 y), Day 0 | 39 Participants |
| GSK2340274A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (18-60 y), Day 21 | 42 Participants |
| GSK2340274A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (18-60 y), Day 21 | 83 Participants |
| GSK2340274A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (18-64 y), Day 21 | 89 Participants |
| GSK2340274A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (>64 y), Day 0 | 76 Participants |
| GSK2340274A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (18-60 y), Day 0 | 44 Participants |
| GSK2340274A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (>60 y), Day 0 | 76 Participants |
| GSK2340274A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (>60 y), Day 21 | 135 Participants |
| GSK2340274A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (18-64 y), Day 0 | 44 Participants |
| GSK2340274A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (>64 y), Day 21 | 129 Participants |
| GSK2340273A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (18-60 y), Day 21 | 79 Participants |
| GSK2340273A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (18-64 y), Day 0 | 57 Participants |
| GSK2340273A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (>60 y), Day 21 | 129 Participants |
| GSK2340273A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (>64 y), Day 21 | 120 Participants |
| GSK2340273A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (18-64 y), Day 21 | 88 Participants |
| GSK2340273A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (>60 y), Day 0 | 76 Participants |
| GSK2340273A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (>64 y), Day 0 | 71 Participants |
| GSK2340273A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (18-60 y), Day 0 | 52 Participants |
| GSK2340273A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (>64 y), Day 21 | 56 Participants |
| GSK2340273A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (>60 y), Day 21 | 58 Participants |
| GSK2340273A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (18-64 y), Day 0 | 23 Participants |
| GSK2340273A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (18-60 y), Day 21 | 44 Participants |
| GSK2340273A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (18-64 y), Day 21 | 46 Participants |
| GSK2340273A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (18-60 y), Day 0 | 21 Participants |
| GSK2340273A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (>64 y), Day 0 | 28 Participants |
| GSK2340273A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (>60 y), Day 0 | 30 Participants |
| GSK2340273A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (>60 y), Day 21 | 62 Participants |
| GSK2340273A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (18-60 y), Day 0 | 22 Participants |
| GSK2340273A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (>60 y), Day 0 | 41 Participants |
| GSK2340273A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (>64 y), Day 0 | 38 Participants |
| GSK2340273A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (18-60 y), Day 21 | 43 Participants |
| GSK2340273A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (18-64 y), Day 0 | 25 Participants |
| GSK2340273A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (>64 y), Day 21 | 58 Participants |
| GSK2340273A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (18-64 y), Day 21 | 47 Participants |
| GSK2340273A F3_2D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (18-64 y), Day 0 | 40 Participants |
| GSK2340273A F3_2D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (18-64 y), Day 21 | 86 Participants |
| GSK2340273A F3_2D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (18-60 y), Day 0 | 37 Participants |
| GSK2340273A F3_2D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (18-60 y), Day 21 | 77 Participants |
| GSK2340273A F3_2D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (>60 y), Day 0 | 83 Participants |
| GSK2340273A F3_2D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (>60 y), Day 21 | 124 Participants |
| GSK2340273A F3_2D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (>64 y), Day 21 | 115 Participants |
| GSK2340273A F3_2D Group | Number of Subjects Seropositive for HI Antibodies Against A/California Virus Strain | A/California strain (>64 y), Day 0 | 80 Participants |
Secondary
Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain
A seropositive subject against the A/California/ virus strain was defined as a subject with H1N1 reciprocal HI antibody titers greater than or equal to (≥) the seropositivity cut-off of 1:10. Results were tabulated according to age strata: subjects between 18 to 60 years (y) old and \> 60 years and subjects between 18 and 64 years old and \> 64 years, respectively.
Time frame: At Days 0 and 182
Population: The analysis was performed on the ATP cohort for immunogenicity, which included all subjects who received the vaccine/ placebo doses on both Days 0 and 21 and from whom assay results for antibodies against A/California-like HA antigen for blood samples taken were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK2340274A F1_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 0 | 54 Participants |
| GSK2340274A F1_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 182 | 87 Participants |
| GSK2340274A F1_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 0 | 89 Participants |
| GSK2340274A F1_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 0 | 46 Participants |
| GSK2340274A F1_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 182 | 136 Participants |
| GSK2340274A F1_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 182 | 75 Participants |
| GSK2340274A F1_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 182 | 124 Participants |
| GSK2340274A F1_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 0 | 81 Participants |
| GSK2340274A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 0 | 28 Participants |
| GSK2340274A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 0 | 33 Participants |
| GSK2340274A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 182 | 61 Participants |
| GSK2340274A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 182 | 66 Participants |
| GSK2340274A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 0 | 25 Participants |
| GSK2340274A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 182 | 42 Participants |
| GSK2340274A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 0 | 30 Participants |
| GSK2340274A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 182 | 47 Participants |
| GSK2340274A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 0 | 38 Participants |
| GSK2340274A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 182 | 40 Participants |
| GSK2340274A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 182 | 60 Participants |
| GSK2340274A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 0 | 24 Participants |
| GSK2340274A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 0 | 39 Participants |
| GSK2340274A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 182 | 56 Participants |
| GSK2340274A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 0 | 23 Participants |
| GSK2340274A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 182 | 44 Participants |
| GSK2340274A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 182 | 85 Participants |
| GSK2340274A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 0 | 44 Participants |
| GSK2340274A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 182 | 133 Participants |
| GSK2340274A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 0 | 44 Participants |
| GSK2340274A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 182 | 127 Participants |
| GSK2340274A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 0 | 76 Participants |
| GSK2340274A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 182 | 79 Participants |
| GSK2340274A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 0 | 76 Participants |
| GSK2340273A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 0 | 55 Participants |
| GSK2340273A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 0 | 50 Participants |
| GSK2340273A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 182 | 114 Participants |
| GSK2340273A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 182 | 72 Participants |
| GSK2340273A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 0 | 73 Participants |
| GSK2340273A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 182 | 81 Participants |
| GSK2340273A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 0 | 68 Participants |
| GSK2340273A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 182 | 105 Participants |
| GSK2340273A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 182 | 52 Participants |
| GSK2340273A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 0 | 22 Participants |
| GSK2340273A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 182 | 50 Participants |
| GSK2340273A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 0 | 20 Participants |
| GSK2340273A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 182 | 45 Participants |
| GSK2340273A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 182 | 43 Participants |
| GSK2340273A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 0 | 31 Participants |
| GSK2340273A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 0 | 29 Participants |
| GSK2340273A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 182 | 44 Participants |
| GSK2340273A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 0 | 41 Participants |
| GSK2340273A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 0 | 38 Participants |
| GSK2340273A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 0 | 23 Participants |
| GSK2340273A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 0 | 20 Participants |
| GSK2340273A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 182 | 40 Participants |
| GSK2340273A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 182 | 54 Participants |
| GSK2340273A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 182 | 50 Participants |
| GSK2340273A F3_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 0 | 38 Participants |
| GSK2340273A F3_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 0 | 35 Participants |
| GSK2340273A F3_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 182 | 84 Participants |
| GSK2340273A F3_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 182 | 76 Participants |
| GSK2340273A F3_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 0 | 79 Participants |
| GSK2340273A F3_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 0 | 82 Participants |
| GSK2340273A F3_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 182 | 108 Participants |
| GSK2340273A F3_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 182 | 116 Participants |
Secondary
Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain
A seropositive subject against the A/California/ virus strain was defined as a subject with H1N1 reciprocal HI antibody titers greater than or equal to (≥) the seropositivity cut-off of 1:10. Results were tabulated according to age strata: subjects between 18 to 60 years (y) old and \> 60 years and subjects between 18 and 64 years old and \> 64 years, respectively.
Time frame: At Days 0 and 42
Population: The analysis was performed on the ATP cohort for immunogenicity, which included all subjects who received the vaccine/ placebo doses on both Days 0 and 21 and from whom assay results for antibodies against A/California-like HA antigen for blood samples taken were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK2340274A F1_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 0 | 25 Participants |
| GSK2340274A F1_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 0 | 24 Participants |
| GSK2340274A F1_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 0 | 39 Participants |
| GSK2340274A F1_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 42 | 61 Participants |
| GSK2340274A F1_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 42 | 64 Participants |
| GSK2340274A F1_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 0 | 38 Participants |
| GSK2340274A F1_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 42 | 39 Participants |
| GSK2340274A F1_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 42 | 42 Participants |
| GSK2340274A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 0 | 27 Participants |
| GSK2340274A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 42 | 44 Participants |
| GSK2340274A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 0 | 24 Participants |
| GSK2340274A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 0 | 33 Participants |
| GSK2340274A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 0 | 36 Participants |
| GSK2340274A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 42 | 39 Participants |
| GSK2340274A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 42 | 68 Participants |
| GSK2340274A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 42 | 63 Participants |
| GSK2340274A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 0 | 22 Participants |
| GSK2340274A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 42 | 68 Participants |
| GSK2340274A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 42 | 63 Participants |
| GSK2340274A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 42 | 40 Participants |
| GSK2340274A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 0 | 38 Participants |
| GSK2340274A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 0 | 21 Participants |
| GSK2340274A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 42 | 45 Participants |
| GSK2340274A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 0 | 39 Participants |
| GSK2340274A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 0 | 42 Participants |
| GSK2340274A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 42 | 67 Participants |
| GSK2340274A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 42 | 44 Participants |
| GSK2340274A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 42 | 63 Participants |
| GSK2340274A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 0 | 23 Participants |
| GSK2340274A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 42 | 40 Participants |
| GSK2340274A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 0 | 42 Participants |
| GSK2340274A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 0 | 23 Participants |
| GSK2340273A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 0 | 26 Participants |
| GSK2340273A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 42 | 39 Participants |
| GSK2340273A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 42 | 59 Participants |
| GSK2340273A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 0 | 31 Participants |
| GSK2340273A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 0 | 33 Participants |
| GSK2340273A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 0 | 28 Participants |
| GSK2340273A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 42 | 42 Participants |
| GSK2340273A F1_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 42 | 56 Participants |
| GSK2340273A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 42 | 59 Participants |
| GSK2340273A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 0 | 22 Participants |
| GSK2340273A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 42 | 45 Participants |
| GSK2340273A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 0 | 20 Participants |
| GSK2340273A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 0 | 29 Participants |
| GSK2340273A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 42 | 61 Participants |
| GSK2340273A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 42 | 43 Participants |
| GSK2340273A F2_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 0 | 31 Participants |
| GSK2340273A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 42 | 47 Participants |
| GSK2340273A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 0 | 40 Participants |
| GSK2340273A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 42 | 56 Participants |
| GSK2340273A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 0 | 37 Participants |
| GSK2340273A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 0 | 25 Participants |
| GSK2340273A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 0 | 22 Participants |
| GSK2340273A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 42 | 52 Participants |
| GSK2340273A F2_1D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 42 | 43 Participants |
| GSK2340273A F3_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 0 | 44 Participants |
| GSK2340273A F3_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 42 | 41 Participants |
| GSK2340273A F3_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 42 | 37 Participants |
| GSK2340273A F3_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 42 | 64 Participants |
| GSK2340273A F3_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 0 | 15 Participants |
| GSK2340273A F3_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 42 | 68 Participants |
| GSK2340273A F3_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 0 | 16 Participants |
| GSK2340273A F3_2D Group | Number of Subjects Seropositive for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 0 | 43 Participants |
Secondary
Number of Subjects With Abnormal Biochemical and Haematological Levels
Among biochemical and haematological parameters assessed were alanine aminotransferase \[ALT\], alkaline phosphatase \[AP\], aspartate aminotransferase \[AST\], basophils \[BAS\], bilirubin \[BIL\], bilirubin conjugated/direct \[BIL/CD\] creatinine \[CREA\], eosinophils \[EOS\], hematocrit \[HEM\], haemoglobin \[Hgb\], lymphocytes \[LYM\], monocytes \[MON\], neutrophils \[NEU\], platelets \[PLA\], red blood cells \[RBC\], blood urea nitrogen \[BUN\] and white blood cells \[WBC\]. Levels of haematological/biochemical parameters assessed in terms of normal laboratory values were - unknown, below, within and above the reference range defined for the specified time point and laboratory parameter.
Time frame: At Days 7, 21, 28, 42 and 182, for subjects between 18-64 years of age
Population: The analysis was performed on the Total Vaccinated cohort included all subjects who received at least 1 study vaccination.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Below | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Within | 93 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Within | 82 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Below | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Within | 86 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Within | 89 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Below | 4 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Within | 92 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Below | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Within | 85 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Within | 91 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Within | 71 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Above | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Below | 5 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Within | 82 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Within | 79 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Within | 91 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Within | 92 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Within | 91 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Within | 86 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Below | 7 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Within | 84 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Below | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Below | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Within | 83 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Within | 87 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Above | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Within | 92 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Within | 90 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Above | 4 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Below | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Below | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Within | 82 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Below | 6 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Within | 85 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Below | 4 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Within | 92 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Within | 87 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Within | 84 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Below | 4 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Below | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Within | 87 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Below | 6 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Within | 92 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Above | 4 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Below | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Within | 69 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Within | 92 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Within | 89 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Below | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Below | 7 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Within | 92 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Within | 86 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Above | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Below | 27 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Within | 91 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Below | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Below | 5 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Within | 88 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Above | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Above | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Below | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Within | 86 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Within | 62 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Below | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Within | 79 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Within | 85 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Within | 92 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Within | 89 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Above | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Within | 91 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Within | 89 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Within | 93 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Above | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Within | 88 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Above | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Within | 72 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Within | 86 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Below | 7 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Within | 88 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Within | 87 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Below | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Below | 29 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Within | 90 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Above | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Within | 89 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Within | 90 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Within | 85 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Above | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Within | 65 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Below | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Within | 88 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Within | 88 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Within | 93 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Within | 92 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Within | 93 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Within | 87 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Within | 92 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Within | 91 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Within | 90 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Within | 88 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Within | 93 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Above | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Within | 90 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Below | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Within | 92 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Below | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Below | 10 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Within | 91 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Below | 21 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Within | 92 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Above | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Above | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Within | 91 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Within | 92 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Below | 5 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Within | 86 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Within | 87 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Within | 85 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Below | 6 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Within | 92 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Below | 9 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Below | 7 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Within | 82 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Below | 21 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Within | 88 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Below | 5 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Within | 85 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Within | 83 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Below | 8 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Below | 5 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Below | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Below | 11 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Within | 79 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Above | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Within | 87 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Below | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Within | 82 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Above | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Above | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Within | 91 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Within | 85 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Below | 18 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Below | 5 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Above | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Below | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Below | 4 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Below | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Within | 91 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Within | 90 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Above | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Below | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Below | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Below | 7 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Within | 79 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Within | 45 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Within | 44 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Within | 42 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Below | 3 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Unknown | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Below | 2 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Within | 44 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Below | 11 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Within | 47 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Within | 44 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Within | 44 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Above | 2 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Below | 3 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Within | 41 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Below | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Within | 47 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Below | 2 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Within | 45 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Within | 36 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Within | 41 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Below | 4 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Below | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Within | 46 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Below | 4 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Unknown | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Within | 45 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Within | 46 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Within | 47 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Below | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Within | 47 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Below | 8 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Within | 42 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Within | 46 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Within | 47 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Within | 46 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Below | 2 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Within | 45 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Within | 46 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Below | 2 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Within | 46 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Below | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Below | 3 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Within | 46 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Below | 5 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Within | 47 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Within | 47 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Within | 45 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Within | 45 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Above | 2 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Unknown | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Below | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Within | 45 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Within | 42 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Within | 45 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Below | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Within | 44 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Below | 3 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Within | 44 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Below | 3 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Within | 46 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Below | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Within | 46 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Within | 42 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Above | 3 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Below | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Within | 36 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Below | 11 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Above | 2 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Within | 44 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Above | 2 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Within | 42 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Unknown | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Unknown | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Within | 45 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Below | 3 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Within | 37 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Within | 47 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Within | 47 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Below | 3 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Within | 46 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Within | 44 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Within | 47 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Within | 47 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Within | 47 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Below | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Within | 47 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Within | 45 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Within | 47 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Within | 47 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Within | 47 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Within | 46 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Within | 46 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Within | 45 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Within | 43 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Within | 47 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Below | 5 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Within | 41 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Within | 47 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Unknown | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Within | 46 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Within | 46 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Within | 44 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Below | 3 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Unknown | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Unknown | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Within | 40 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Within | 44 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Below | 5 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Below | 14 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Within | 46 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Within | 41 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Within | 47 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Within | 33 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Unknown | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Within | 47 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Within | 43 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Below | 4 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Within | 46 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Within | 43 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Within | 47 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Below | 4 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Unknown | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Within | 43 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Within | 47 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Below | 2 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Below | 2 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Within | 42 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Below | 4 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Within | 47 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Below | 4 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Within | 45 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Within | 36 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Below | 11 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Within | 39 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Below | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Within | 45 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Below | 6 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Within | 45 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Within | 45 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Unknown | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Within | 46 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Below | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Above | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Within | 39 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Within | 47 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Above | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Unknown | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Above | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Unknown | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Within | 47 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Below | 4 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Within | 47 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Above | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Below | 6 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Above | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Within | 46 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Unknown | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Within | 44 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Within | 42 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Within | 46 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Within | 44 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Above | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Within | 44 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Within | 40 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Within | 45 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Within | 42 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Below | 4 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Within | 46 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Within | 37 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Above | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Above | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Within | 35 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Within | 47 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Below | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Within | 46 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Below | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Below | 4 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Unknown | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Above | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Unknown | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Within | 46 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Within | 45 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Within | 47 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Above | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Within | 41 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Within | 47 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Below | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Below | 4 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Within | 45 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Above | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Unknown | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Unknown | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Above | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Within | 47 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Within | 46 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Within | 42 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Within | 44 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Within | 45 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Within | 46 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Unknown | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Unknown | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Above | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Below | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Unknown | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Within | 44 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Above | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Within | 41 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Within | 47 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Above | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Within | 43 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Below | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Within | 45 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Below | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Within | 43 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Below | 9 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Unknown | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Within | 47 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Within | 45 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Below | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Below | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Unknown | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Within | 44 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Below | 8 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Below | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Above | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Within | 44 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Within | 45 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Below | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Below | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Unknown | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Within | 43 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Unknown | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Within | 46 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Unknown | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Within | 46 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Below | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Within | 37 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Above | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Within | 47 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Within | 47 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Within | 46 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Within | 47 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Within | 43 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Unknown | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Below | 5 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Below | 10 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Above | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Above | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Below | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Within | 45 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Below | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Below | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Within | 47 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Within | 44 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Unknown | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Within | 37 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Above | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Below | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Within | 46 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Below | 6 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Below | 3 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Within | 40 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Unknown | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Within | 46 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Above | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Below | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Below | 9 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Below | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Below | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Above | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Within | 45 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Within | 44 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Below | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Below | 8 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Within | 45 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Unknown | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Within | 41 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Above | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Within | 43 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Below | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Within | 42 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Above | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Below | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Below | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Within | 45 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Below | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Within | 41 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Within | 44 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Above | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Within | 47 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Below | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Within | 42 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Above | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Within | 45 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Within | 46 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Above | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Within | 44 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Above | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Within | 47 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Within | 47 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Within | 44 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Within | 46 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Within | 47 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Within | 46 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Within | 46 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Within | 47 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Within | 47 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Within | 47 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Within | 46 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Within | 45 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Above | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Within | 45 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Above | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Below | 21 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Below | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Above | 3 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Within | 90 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Within | 86 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Unknown | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Within | 88 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Above | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Above | 3 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Within | 91 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Within | 81 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Below | 6 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Within | 83 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Within | 88 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Below | 4 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Within | 86 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Above | 4 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Below | 3 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Within | 88 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Below | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Above | 5 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Below | 3 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Below | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Below | 17 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Within | 91 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Within | 87 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Within | 86 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Within | 90 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Within | 74 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Below | 3 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Below | 17 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Below | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Within | 88 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Within | 85 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Above | 3 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Above | 3 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Unknown | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Within | 73 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Above | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Below | 3 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Within | 88 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Within | 81 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Below | 3 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Within | 91 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Above | 3 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Within | 87 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Within | 90 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Within | 84 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Below | 3 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Below | 4 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Below | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Above | 3 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Above | 3 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Within | 88 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Within | 90 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Within | 89 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Within | 81 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Above | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Within | 88 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Below | 18 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Within | 89 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Unknown | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Below | 8 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Within | 84 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Within | 87 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Within | 86 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Below | 5 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Within | 89 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Within | 90 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Within | 86 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Within | 91 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Within | 85 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Below | 18 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Within | 90 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Within | 91 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Within | 91 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Within | 89 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Below | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Below | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Within | 86 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Within | 89 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Within | 87 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Within | 87 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Within | 83 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Below | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Below | 4 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Within | 87 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Within | 87 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Unknown | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Within | 88 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Below | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Within | 86 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Within | 73 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Within | 91 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Below | 8 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Within | 83 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Within | 90 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Within | 91 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Unknown | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Below | 7 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Within | 87 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Above | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Below | 5 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Within | 84 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Within | 70 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Above | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Within | 87 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Unknown | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Below | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Below | 5 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Within | 86 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Below | 10 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Within | 78 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Within | 91 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Within | 89 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Below | 4 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Above | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Within | 89 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Within | 85 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Above | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Below | 6 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Within | 86 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Below | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Within | 70 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Within | 84 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Below | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Below | 3 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Within | 87 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Unknown | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Below | 3 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Within | 85 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Below | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Above | 3 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Above | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Unknown | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Above | 3 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Below | 5 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Within | 84 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Above | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Below | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Within | 88 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Unknown | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Below | 6 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Unknown | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Within | 90 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Above | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Within | 86 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Above | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Within | 90 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Within | 90 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Within | 90 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Within | 87 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Within | 90 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Within | 89 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Above | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Within | 91 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Within | 88 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Within | 90 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Within | 88 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Above | 3 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Within | 91 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Within | 92 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Within | 82 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Below | 14 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Below | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Above | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Above | 3 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Below | 12 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Within | 82 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Within | 88 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Within | 89 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Within | 89 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Above | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Within | 83 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Within | 77 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Below | 3 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Within | 85 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Within | 89 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Below | 5 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Within | 88 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Above | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Within | 87 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Below | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Below | 21 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Above | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Below | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Within | 91 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Below | 4 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Within | 92 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Above | 5 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Above | 3 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Below | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Within | 91 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Within | 87 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Below | 13 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Below | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Below | 5 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Above | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Below | 12 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Below | 5 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Below | 8 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Within | 88 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Above | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Above | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Above | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Above | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Within | 90 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Below | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Below | 7 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Within | 90 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Within | 89 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Within | 92 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Within | 85 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Within | 90 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Within | 88 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Above | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Above | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Within | 91 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Within | 89 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Within | 83 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Below | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Within | 86 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Within | 90 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Below | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Below | 7 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Above | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Within | 89 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Within | 89 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Above | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Within | 91 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Within | 91 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Within | 89 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Within | 83 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Within | 91 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Below | 3 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Above | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Above | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Above | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Within | 92 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Within | 90 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Within | 88 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Above | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Below | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Within | 77 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Within | 87 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Within | 86 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Above | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Below | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Below | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Within | 79 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Within | 86 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Within | 88 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Below | 8 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Within | 90 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Within | 89 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Below | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Above | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Within | 89 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Within | 83 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Within | 88 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Within | 91 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Above | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Below | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Within | 90 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Above | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Within | 89 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Below | 5 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Above | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Above | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Below | 19 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Within | 81 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Within | 68 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Within | 75 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Above | 4 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Within | 87 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Within | 86 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Below | 5 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Above | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Within | 80 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Within | 92 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Above | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Within | 78 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Above | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Below | 3 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Below | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Within | 80 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Within | 87 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Within | 86 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Within | 91 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Within | 84 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Above | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Below | 3 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Below | 3 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Below | 4 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Above | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Within | 70 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Within | 88 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Below | 7 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Within | 75 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Within | 83 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Within | 91 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Below | 7 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Below | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Within | 87 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Below | 16 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Above | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Above | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Within | 89 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Within | 91 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Below | 6 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Above | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Within | 86 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Below | 15 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Below | 3 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Within | 86 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Within | 90 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Below | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Above | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Above | 3 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Within | 89 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Within | 91 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Above | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Within | 87 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Within | 91 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Within | 89 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Above | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Within | 90 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Above | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Within | 89 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Above | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Within | 76 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Above | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Within | 47 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Within | 48 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Above | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Unknown | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Within | 34 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Unknown | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Above | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Below | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Within | 38 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Within | 46 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Above | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Within | 47 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Within | 47 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Below | 9 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Within | 44 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Within | 43 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Below | 13 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Below | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Below | 8 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Within | 47 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Unknown | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Unknown | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Within | 47 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Unknown | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Within | 47 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Within | 47 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Within | 47 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Unknown | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Within | 47 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Below | 3 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Within | 46 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Within | 46 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Above | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Within | 47 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Above | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Within | 45 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Above | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Within | 48 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Within | 46 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Unknown | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Above | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Above | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Within | 43 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Below | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Within | 46 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Above | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Unknown | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Below | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Within | 46 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Within | 41 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Within | 40 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Below | 3 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Below | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Below | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Within | 46 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Below | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Unknown | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Within | 47 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Within | 46 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Within | 48 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Within | 49 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Within | 46 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Above | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Below | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Unknown | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Within | 47 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Within | 39 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Within | 43 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Within | 47 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Unknown | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Below | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Unknown | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Within | 48 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Within | 45 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Within | 43 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Within | 46 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Unknown | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Above | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Below | 8 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Above | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Below | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Within | 48 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Below | 3 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Unknown | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Within | 44 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Within | 47 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Within | 46 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Below | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Below | 3 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Below | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Above | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Within | 46 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Unknown | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Within | 48 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Within | 45 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Unknown | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Within | 47 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Within | 48 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Within | 46 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Unknown | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Within | 46 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Within | 43 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Unknown | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Within | 46 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Below | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Within | 49 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Within | 46 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Within | 46 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Below | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Above | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Within | 48 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Below | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Below | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Within | 46 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Within | 46 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Below | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Unknown | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Within | 44 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Below | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Within | 42 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Unknown | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Unknown | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Within | 49 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Within | 47 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Below | 4 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Within | 49 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Below | 6 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Within | 46 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Below | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Above | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Within | 47 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Within | 45 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Above | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Within | 47 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Within | 47 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Above | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Within | 47 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Within | 47 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Within | 46 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Above | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Within | 45 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Within | 49 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Within | 47 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Within | 48 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Within | 47 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Below | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Within | 49 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Above | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Within | 49 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Within | 48 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Below | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Within | 48 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Below | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Below | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Above | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Within | 47 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Below | 3 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Below | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Within | 45 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Within | 46 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Below | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Within | 48 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Above | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Within | 47 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Within | 46 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Below | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Below | 3 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Unknown | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Above | 3 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Below | 4 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Within | 44 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Within | 46 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Within | 45 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Below | 3 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Within | 42 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Within | 47 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Below | 3 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Within | 46 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Within | 47 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Within | 47 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Below | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Within | 46 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Within | 42 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Below | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Within | 46 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Within | 47 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Below | 4 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Below | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Below | 3 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Within | 46 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Within | 47 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Within | 45 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Above | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Below | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Within | 39 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Within | 45 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Unknown | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Within | 44 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Within | 44 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Within | 47 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Within | 47 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Within | 44 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Within | 46 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Below | 7 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Below | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Below | 4 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Below | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Within | 41 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Below | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Unknown | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Within | 46 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Within | 46 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Within | 46 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Within | 45 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Within | 47 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Below | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Unknown | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Within | 46 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Within | 44 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Unknown | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Within | 46 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Within | 43 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Within | 46 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Within | 44 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Below | 3 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Within | 43 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Unknown | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Within | 46 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Within | 45 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Within | 44 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Below | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Within | 40 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Within | 46 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Unknown | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Below | 3 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Within | 45 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Within | 44 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Within | 38 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Below | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Below | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Above | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Within | 46 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Within | 46 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Above | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Within | 42 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Within | 46 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Below | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Within | 39 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Within | 46 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Above | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Below | 7 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Within | 42 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Above | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Within | 41 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Unknown | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Within | 43 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Within | 46 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Above | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Below | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Within | 39 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Below | 4 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Below | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Within | 46 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Above | 3 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Below | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Unknown | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Below | 3 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Above | 3 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Below | 4 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Below | 8 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Within | 41 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Within | 46 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Above | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Within | 46 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Below | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Within | 44 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Within | 42 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Within | 47 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Below | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Unknown | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Below | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Within | 43 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Within | 45 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Above | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Within | 45 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Within | 43 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Above | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Within | 46 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Within | 46 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Within | 45 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Within | 45 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Within | 46 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Within | 46 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Within | 46 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Within | 46 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Within | 47 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Within | 46 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Below | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Within | 42 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Within | 46 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Below | 5 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Below | 3 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Below | 9 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Within | 44 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Within | 43 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Unknown | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Below | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Within | 43 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Below | 4 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Within | 45 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Within | 42 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Below | 6 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Above | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Above | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Above | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Within | 87 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Within | 78 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Above | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Unknown | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Within | 88 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Within | 91 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Above | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Above | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Unknown | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Unknown | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Above | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Within | 90 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Within | 91 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Above | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Within | 83 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Above | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Unknown | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Above | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Above | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Within | 86 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Below | 4 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Above | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Below | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Within | 76 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Unknown | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Within | 91 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Within | 87 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Below | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Above | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Unknown | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Within | 88 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Above | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Above | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Within | 84 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Above | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Within | 83 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Below | 6 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Below | 23 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Within | 86 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Below | 6 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Above | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Below | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Unknown | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Above | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Within | 81 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Within | 91 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Above | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Above | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Below | 18 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Unknown | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Below | 7 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Within | 88 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Below | 10 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Below | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Unknown | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Within | 84 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Below | 4 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Within | 91 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Within | 68 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Above | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Above | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Within | 76 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Unknown | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Within | 90 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Within | 86 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Above | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Below | 5 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Unknown | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Within | 71 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Above | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Unknown | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Above | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Below | 5 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Within | 87 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Above | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Within | 90 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Within | 91 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Within | 90 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Within | 87 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Unknown | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Above | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Above | 4 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Within | 87 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Below | 6 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Within | 90 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Within | 86 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Within | 90 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Below | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Above | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Unknown | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Within | 88 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Within | 89 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Unknown | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Within | 86 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Above | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Unknown | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Within | 89 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Below | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Within | 85 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Below | 4 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Within | 79 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Within | 89 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Within | 89 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Above | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Below | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Within | 79 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Below | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Within | 92 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Within | 90 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Within | 89 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Within | 89 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Below | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Within | 81 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Above | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Below | 19 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Below | 11 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Above | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Within | 90 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Within | 89 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Below | 13 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Below | 6 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Below | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Above | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Within | 88 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Below | 15 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Within | 91 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Within | 88 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Within | 91 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Unknown | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Unknown | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Below | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Above | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Above | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Above | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Within | 91 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Within | 90 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Within | 85 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Below | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Above | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Above | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Above | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Within | 91 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Within | 87 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Within | 92 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Within | 85 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Above | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Within | 86 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Within | 88 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Above | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Above | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Above | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Above | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Below | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Unknown | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Unknown | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Below | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Unknown | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Above | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Within | 88 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Below | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Within | 90 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Within | 92 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Within | 92 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Within | 92 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Within | 84 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Within | 90 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Within | 89 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Unknown | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Unknown | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Within | 88 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Unknown | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Above | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Below | 4 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Below | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Above | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Within | 85 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Unknown | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Below | 4 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Above | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Within | 90 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Within | 82 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Unknown | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Unknown | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Below | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Above | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Within | 85 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Within | 90 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Within | 88 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Within | 90 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Within | 91 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Within | 88 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Below | 9 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Above | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Within | 92 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Below | 4 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Unknown | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Above | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Below | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Below | 9 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Within | 90 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Unknown | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Within | 85 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Within | 72 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Below | 4 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Unknown | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Below | 12 Participants |
Secondary
Number of Subjects With Abnormal Biochemical and Haematological Levels
Among biochemical and haematological parameters assessed were alanine aminotransferase \[ALT\], alkaline phosphatase \[AP\], aspartate aminotransferase \[AST\], basophils \[BAS\], bilirubin \[BIL\], bilirubin conjugated/direct \[BIL/CD\] creatinine \[CREA\], eosinophils \[EOS\], hematocrit \[HEM\], haemoglobin \[Hgb\], lymphocytes \[LYM\], monocytes \[MON\], neutrophils \[NEU\], platelets \[PLA\], red blood cells \[RBC\], blood urea nitrogen \[BUN\] and white blood cells \[WBC\]. Levels of haematological/biochemical parameters assessed in terms of normal laboratory values were - unknown, below, within and above the reference range defined for the specified time point and laboratory parameter.
Time frame: At Days 7, 21, 28, 42 and 182, for subjects > 64 years of age
Population: The analysis was performed on the Total Vaccinated cohort, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Above | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Above | 4 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Within | 125 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Within | 122 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Below | 12 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Within | 123 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Within | 122 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Below | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Within | 128 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Above | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Within | 124 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Below | 15 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Below | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Within | 126 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Within | 125 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Within | 126 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Above | 4 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Below | 11 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Below | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Within | 123 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Within | 120 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Within | 122 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Within | 125 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Within | 128 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Within | 128 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Above | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Below | 13 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Within | 126 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Below | 8 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Above | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Above | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Within | 116 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Above | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Above | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Below | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Above | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Within | 124 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Below | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Within | 127 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Within | 128 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Above | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Unknown | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Within | 127 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Within | 121 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Within | 122 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Above | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Above | 6 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Below | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Within | 127 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Above | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Below | 4 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Above | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Within | 122 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Above | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Within | 123 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Within | 127 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Below | 4 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Unknown | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Unknown | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Above | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Within | 126 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Above | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Within | 126 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Below | 5 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Above | 4 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Within | 112 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Below | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Above | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Unknown | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Above | 6 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Within | 121 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Below | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Within | 127 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Within | 126 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Within | 123 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Within | 127 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Unknown | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Below | 4 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Below | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Within | 127 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Below | 6 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Above | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Below | 4 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Within | 109 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Below | 6 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Within | 119 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Above | 4 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Below | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Within | 122 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Above | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Below | 13 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Within | 115 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Within | 121 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Within | 125 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Within | 112 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Within | 124 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Below | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Within | 124 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Below | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Within | 116 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Within | 107 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Within | 129 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Above | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Within | 115 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Below | 6 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Within | 123 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Below | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Above | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Within | 111 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Unknown | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Within | 123 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Unknown | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Below | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Within | 118 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Below | 4 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Below | 15 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Within | 125 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Within | 125 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Above | 4 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Below | 4 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Below | 4 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Below | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Within | 119 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Below | 4 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Within | 121 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Above | 6 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Above | 4 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Above | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Within | 128 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Below | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Within | 124 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Unknown | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Within | 118 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Below | 20 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Within | 127 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Within | 118 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Above | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Within | 126 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Within | 120 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Within | 121 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Within | 120 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Within | 119 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Within | 127 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Above | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Below | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Above | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Within | 120 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Below | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Above | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Within | 120 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Above | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Within | 121 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Within | 126 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Below | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Below | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Above | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Within | 124 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Within | 123 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Within | 119 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Within | 112 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Within | 125 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Below | 7 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Within | 125 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Unknown | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Above | 4 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Below | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Above | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Within | 123 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Within | 126 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Within | 118 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Below | 14 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Above | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Below | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Below | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Above | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Above | 5 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Unknown | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Within | 112 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Unknown | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Above | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Within | 126 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Within | 124 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Below | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Below | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Within | 125 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Below | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Above | 3 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Below | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Within | 56 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Within | 65 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Below | 10 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Within | 63 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Within | 63 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Within | 65 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Unknown | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Within | 65 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Within | 62 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Unknown | 2 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Unknown | 2 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Within | 63 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Within | 62 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Above | 2 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Within | 62 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Within | 66 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Below | 6 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Within | 66 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Within | 62 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Within | 66 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Within | 66 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Below | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Within | 65 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Below | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Within | 66 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Unknown | 2 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Within | 63 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Within | 63 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Within | 65 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Below | 7 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Below | 2 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Within | 59 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Unknown | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Within | 65 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Unknown | 2 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Below | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Within | 66 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Below | 4 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Within | 65 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Within | 65 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Within | 65 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Within | 65 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Within | 63 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Within | 65 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Within | 66 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Within | 63 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Within | 65 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Within | 65 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Unknown | 2 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Within | 66 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Within | 63 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Within | 64 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Within | 66 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Within | 66 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Within | 66 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Within | 65 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Within | 62 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Unknown | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Within | 65 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Below | 2 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Within | 63 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Below | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Within | 66 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Within | 63 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Within | 66 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Within | 62 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Unknown | 2 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Within | 66 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Within | 66 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Unknown | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Within | 61 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Within | 66 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Unknown | 2 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Within | 61 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Unknown | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Within | 66 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Within | 64 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Unknown | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Within | 59 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Within | 63 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Below | 7 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Below | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Within | 65 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Above | 3 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Within | 56 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Within | 66 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Below | 2 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Within | 64 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Within | 64 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Unknown | 2 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Below | 3 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Unknown | 2 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Below | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Within | 61 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Within | 65 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Below | 10 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Within | 66 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Within | 56 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Below | 7 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Below | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Within | 60 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Above | 2 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Within | 59 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Below | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Within | 62 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Below | 2 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Within | 60 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Within | 66 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Above | 3 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Unknown | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Within | 59 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Below | 7 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Within | 63 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Within | 65 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Within | 59 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Within | 63 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Within | 64 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Within | 63 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Below | 5 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Within | 63 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Within | 61 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Within | 64 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Above | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Within | 63 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Below | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Within | 63 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Below | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Within | 66 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Below | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Below | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Above | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Within | 56 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Within | 66 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Unknown | 2 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Below | 6 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Within | 61 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Within | 63 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Above | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Below | 5 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Above | 3 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Within | 58 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Within | 60 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Within | 62 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Below | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Within | 61 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Within | 59 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Within | 61 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Above | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Within | 63 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Above | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Within | 62 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Within | 63 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Within | 55 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Below | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Within | 62 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Within | 62 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Above | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Below | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Within | 62 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Within | 63 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Within | 65 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Unknown | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Unknown | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Below | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Below | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Below | 5 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Within | 60 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Within | 62 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Below | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Within | 60 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Unknown | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Within | 62 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Below | 7 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Within | 60 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Below | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Within | 56 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Within | 65 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Within | 53 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Below | 7 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Below | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Within | 62 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Within | 62 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Unknown | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Above | 4 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Below | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Within | 63 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Below | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Within | 54 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Within | 58 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Within | 61 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Unknown | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Below | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Below | 7 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Within | 65 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Within | 65 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Above | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Unknown | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Within | 64 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Within | 63 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Within | 62 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Above | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Within | 63 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Within | 63 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Within | 59 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Below | 6 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Above | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Within | 57 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Unknown | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Within | 63 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Unknown | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Below | 7 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Below | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Within | 63 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Below | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Within | 62 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Above | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Within | 60 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Above | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Unknown | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Below | 12 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Within | 63 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Within | 57 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Above | 3 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Unknown | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Below | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Within | 56 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Within | 63 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Above | 4 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Unknown | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Within | 62 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Unknown | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Below | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Within | 63 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Unknown | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Within | 60 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Above | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Above | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Within | 62 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Within | 63 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Unknown | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Within | 65 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Within | 62 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Within | 63 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Within | 61 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Above | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Within | 65 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Below | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Within | 61 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Within | 62 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Below | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Above | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Above | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Within | 64 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Above | 3 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Within | 61 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Above | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Below | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Within | 54 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Within | 62 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Above | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Within | 62 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Below | 9 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Unknown | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Within | 56 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Above | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Within | 65 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Below | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Above | 3 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Within | 61 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Within | 64 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Below | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Below | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Within | 62 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Above | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Within | 58 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Below | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Within | 53 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Below | 8 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Within | 63 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Within | 62 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Within | 65 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Within | 63 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Above | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Below | 3 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Within | 63 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Within | 62 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Above | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Above | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Within | 61 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Within | 63 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Within | 63 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Within | 63 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Within | 63 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Within | 65 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Below | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Within | 60 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Unknown | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Above | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Below | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Above | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Within | 127 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Above | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Unknown | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Above | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Within | 130 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Unknown | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Within | 129 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Within | 129 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Within | 128 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Unknown | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Within | 128 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Above | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Unknown | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Within | 128 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Within | 130 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Unknown | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Within | 128 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Unknown | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Within | 126 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Above | 3 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Within | 128 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Within | 129 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Unknown | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Within | 129 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Above | 3 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Within | 129 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Unknown | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Within | 129 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Within | 129 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Unknown | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Within | 128 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Within | 127 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Within | 127 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Within | 129 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Within | 128 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Within | 128 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Above | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Within | 128 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Within | 128 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Above | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Within | 128 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Within | 129 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Above | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Below | 15 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Within | 129 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Below | 13 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Within | 117 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Below | 3 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Within | 124 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Above | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Within | 127 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Below | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Unknown | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Below | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Unknown | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Within | 113 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Above | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Below | 20 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Within | 118 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Within | 110 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Above | 4 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Above | 4 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Within | 130 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Unknown | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Below | 5 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Below | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Above | 5 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Within | 129 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Below | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Above | 5 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Below | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Above | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Above | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Unknown | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Unknown | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Below | 3 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Within | 122 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Unknown | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Within | 117 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Above | 5 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Within | 124 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Within | 126 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Within | 124 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Below | 3 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Within | 130 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Above | 3 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Within | 127 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Above | 3 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Below | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Within | 129 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Above | 5 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Within | 127 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Below | 15 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Within | 125 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Below | 14 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Above | 3 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Unknown | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Within | 121 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Within | 128 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Below | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Within | 125 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Within | 129 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Below | 3 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Within | 108 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Below | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Within | 128 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Below | 3 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Below | 4 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Above | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Unknown | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Below | 3 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Within | 120 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Within | 126 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Within | 108 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Within | 128 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Below | 12 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Above | 4 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Within | 121 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Within | 126 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Within | 125 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Below | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Above | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Below | 12 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Within | 126 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Within | 128 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Within | 118 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Above | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Below | 4 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Above | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Within | 130 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Within | 126 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Within | 127 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Within | 126 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Within | 128 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Below | 11 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Below | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Within | 126 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Below | 3 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Above | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Below | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Within | 125 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Within | 127 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Within | 130 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Unknown | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Within | 117 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Within | 123 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Unknown | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Within | 126 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Above | 3 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Below | 12 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Above | 3 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Unknown | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Below | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Unknown | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Within | 128 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Above | 3 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Below | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Within | 128 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Below | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Unknown | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Below | 21 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Above | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Above | 3 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Within | 115 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Within | 130 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Unknown | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Within | 127 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Below | 3 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Unknown | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Below | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Unknown | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Unknown | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Below | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Below | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Within | 124 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Below | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Within | 122 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Below | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Within | 127 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Within | 117 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Above | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Below | 7 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Unknown | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Within | 130 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Within | 129 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Above | 3 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Within | 129 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Above | 3 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Unknown | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Above | 6 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Above | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Below | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Unknown | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Above | 4 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Unknown | 3 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Above | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Within | 123 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Unknown | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Above | 3 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Above | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Within | 128 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Above | 5 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Unknown | 3 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Below | 13 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Within | 127 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Within | 127 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Within | 120 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Below | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Within | 123 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Below | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Below | 4 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Unknown | 3 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Above | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Within | 126 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Above | 3 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Within | 124 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Within | 129 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Below | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Above | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Above | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Within | 130 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Below | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Unknown | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Below | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Above | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Below | 4 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Above | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Unknown | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Above | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Below | 5 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Within | 129 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Above | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Within | 124 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Below | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Below | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Within | 126 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Below | 15 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Above | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Within | 129 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Above | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Above | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Within | 122 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Below | 5 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Within | 114 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Within | 129 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Above | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Within | 127 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Within | 128 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Unknown | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Below | 7 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Above | 3 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Above | 4 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Unknown | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Within | 128 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Unknown | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Below | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Within | 128 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Above | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Below | 16 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Within | 127 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Within | 125 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Above | 3 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Above | 6 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Within | 125 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Below | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Within | 126 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Above | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Above | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Unknown | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Below | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Within | 125 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Above | 4 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Within | 129 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Within | 120 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Unknown | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Within | 127 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Within | 122 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Above | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Within | 127 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Above | 4 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Within | 127 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Above | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Below | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Within | 126 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Within | 118 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Within | 129 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Within | 129 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Below | 15 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Within | 130 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Above | 4 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Above | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Within | 128 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Within | 125 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Above | 3 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Within | 124 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Above | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Within | 121 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Below | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Within | 129 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Unknown | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Within | 129 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Below | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Below | 12 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Unknown | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Unknown | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Below | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Below | 4 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Within | 114 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Within | 124 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Within | 130 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Above | 3 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Below | 4 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Below | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Within | 125 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Below | 5 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Above | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Above | 3 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Below | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Within | 129 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Unknown | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Unknown | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Above | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Below | 5 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Within | 126 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Within | 129 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Unknown | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Above | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Within | 127 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Unknown | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Above | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Below | 3 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Within | 129 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Below | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Within | 126 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Below | 3 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Within | 130 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Above | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Above | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Within | 127 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Within | 125 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Within | 127 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Within | 127 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Within | 126 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Above | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Within | 114 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Within | 126 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Within | 124 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Above | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Unknown | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Within | 128 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Above | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Below | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Within | 126 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Below | 4 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Below | 10 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Within | 120 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Within | 123 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Below | 7 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Above | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Within | 122 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Above | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Within | 114 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Within | 126 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Within | 122 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Within | 112 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Within | 126 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Unknown | 3 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Below | 8 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Within | 121 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Below | 7 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Unknown | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Unknown | 3 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Below | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Within | 120 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Below | 5 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Within | 116 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Above | 7 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Within | 120 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Above | 4 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Unknown | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Within | 125 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Above | 3 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Unknown | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Within | 121 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Above | 4 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Within | 122 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Above | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Within | 128 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Unknown | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Unknown | 3 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Within | 125 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Below | 3 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Above | 4 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Within | 126 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Within | 123 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Below | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Below | 3 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Within | 125 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Above | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Unknown | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Within | 123 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Above | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Above | 4 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Below | 9 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Within | 64 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Within | 62 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Within | 58 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Within | 65 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Within | 64 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Within | 57 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Within | 62 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Within | 58 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Within | 65 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Within | 62 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Within | 65 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Below | 6 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Within | 61 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Above | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Below | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Below | 3 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Below | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Within | 64 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Within | 62 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Within | 63 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Within | 63 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Within | 65 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Above | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Below | 5 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Below | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Within | 64 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Above | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Within | 63 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Within | 61 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Below | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Below | 6 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Within | 64 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Within | 65 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Within | 65 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Within | 62 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Below | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Within | 62 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Within | 65 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Within | 54 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Above | 3 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Below | 3 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Unknown | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Within | 63 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Below | 5 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Above | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Within | 62 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Within | 63 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Within | 64 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Within | 62 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Above | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Within | 57 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Below | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Unknown | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Within | 56 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Within | 65 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Below | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Within | 64 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Below | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Below | 3 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Within | 65 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Within | 62 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Within | 62 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Within | 63 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Below | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Unknown | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Above | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Below | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Unknown | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Below | 4 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Unknown | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Within | 64 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Above | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Above | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Within | 61 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Above | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Unknown | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Within | 65 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Within | 64 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Within | 63 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Below | 3 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Within | 60 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Above | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Below | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Within | 64 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Within | 62 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Within | 65 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Above | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Within | 63 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Below | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Below | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Below | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Below | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Within | 65 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Within | 65 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Within | 65 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Above | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Unknown | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Within | 65 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Within | 64 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Within | 64 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Unknown | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Unknown | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Within | 62 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Within | 64 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Above | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Below | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Above | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Within | 65 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Below | 11 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Above | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Within | 63 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Unknown | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Within | 63 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Within | 64 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Within | 64 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Within | 63 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Above | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Above | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Within | 62 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Below | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Above | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Within | 64 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Unknown | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Unknown | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Within | 65 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Below | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Unknown | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Below | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Unknown | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Within | 65 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Within | 63 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Within | 65 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Within | 64 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Below | 5 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Above | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Below | 4 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Within | 60 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Above | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Above | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Within | 64 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Unknown | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Below | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Unknown | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Within | 59 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Below | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Within | 65 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Below | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Unknown | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Within | 63 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Unknown | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Below | 3 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Within | 65 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Within | 64 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Below | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Below | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Above | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Within | 57 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Within | 65 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Within | 65 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Within | 65 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Below | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Below | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Within | 65 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Below | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Below | 8 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Within | 65 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Above | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Above | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Within | 62 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Below | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Above | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Unknown | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Below | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Within | 62 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Within | 60 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Below | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Unknown | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Above | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Within | 62 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Below | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Within | 61 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Above | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Within | 61 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Within | 63 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Within | 60 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Within | 63 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Unknown | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Within | 61 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Below | 3 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Within | 60 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Below | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Within | 60 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Within | 61 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Within | 61 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Below | 5 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Unknown | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Unknown | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Within | 58 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Within | 61 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Below | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Within | 61 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Within | 64 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Within | 62 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Unknown | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Within | 63 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Unknown | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Unknown | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Within | 62 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Within | 63 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Unknown | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Within | 63 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Below | 8 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Within | 62 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Within | 63 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Below | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Within | 62 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Within | 62 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Within | 56 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Above | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Above | 4 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Within | 62 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Within | 60 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Unknown | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Within | 61 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Within | 56 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Unknown | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Unknown | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Below | 4 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Below | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Unknown | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Below | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Above | 3 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Unknown | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Below | 6 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Within | 63 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Within | 58 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Within | 63 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Within | 63 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Within | 63 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Within | 63 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Below | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Within | 63 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Within | 63 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Within | 64 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Above | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Within | 60 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Within | 56 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Within | 59 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Above | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Within | 58 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Below | 5 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Below | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Below | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Within | 59 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Below | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Within | 60 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Within | 60 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Unknown | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Above | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Unknown | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Within | 60 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Unknown | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Below | 6 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Within | 61 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Below | 5 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Unknown | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Below | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Within | 63 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Within | 64 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Within | 61 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Within | 56 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Within | 60 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Below | 4 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Unknown | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Within | 61 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Within | 62 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Within | 56 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Below | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Within | 62 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Within | 54 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Below | 3 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Below | 4 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Below | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Within | 63 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Below | 7 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Unknown | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Within | 62 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Within | 54 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Unknown | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Within | 63 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Within | 56 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Unknown | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Below | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Below | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Below | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Below | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Within | 63 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Within | 56 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Above | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Within | 61 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Unknown | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Above | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Above | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Within | 63 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Within | 63 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Within | 62 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Within | 63 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Below | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Unknown | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Within | 59 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Unknown | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Within | 61 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Below | 3 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Within | 63 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Below | 5 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Unknown | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Within | 63 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Below | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Within | 64 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Within | 61 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Below | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Within | 57 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Within | 62 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Below | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Below | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Below | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Below | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Within | 62 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Below | 3 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Below | 9 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Within | 63 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Within | 62 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Below | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Unknown | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Within | 55 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Within | 63 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Unknown | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Below | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Above | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Within | 63 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Above | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Within | 122 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Within | 116 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Within | 125 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Above | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Below | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Within | 123 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Above | 4 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Above | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Within | 129 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Unknown | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Within | 125 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Above | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Below | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Below | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Within | 128 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Below | 6 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Below | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Within | 124 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Above | 4 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Unknown | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Above | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Within | 130 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Above | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Above | 4 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Within | 130 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Below | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Unknown | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Within | 128 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Within | 129 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Below | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Within | 129 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Above | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Within | 128 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Within | 129 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Within | 130 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Below | 8 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Below | 5 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Above | 5 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Above | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Within | 109 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Unknown | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Within | 118 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Below | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Within | 127 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Above | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Above | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Unknown | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Above | 4 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Below | 20 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Below | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Within | 119 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Within | 124 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Above | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Within | 124 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Above | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Within | 130 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Within | 120 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Below | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Above | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Within | 119 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Above | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Below | 9 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Below | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Below | 6 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Within | 115 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Below | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Below | 14 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Above | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Within | 128 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Above | 4 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 21 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Below | 6 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Below | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Within | 119 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Unknown | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Within | 115 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Above | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 7 | Below | 15 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Within | 124 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Above | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Above | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Below | 6 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Within | 129 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Above | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Above | 6 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Within | 124 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Below | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 42 | Unknown | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Above | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Above | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Above | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 28 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Within | 126 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 7 | Within | 129 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 28 | Below | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 21 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 21 | Within | 124 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Below | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 7 | Within | 129 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 182 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Within | 127 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 182 | Below | 21 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 21 | Below | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 42 | Above | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Within | 122 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Within | 129 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 42 | Within | 123 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 182 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Unknown | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 182 | Below | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Unknown | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Within | 129 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Below | 5 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Below | 5 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Within | 127 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 7 | Within | 129 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Below | 11 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Below | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Above | 5 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Above | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Unknown | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 182 | Below | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 7 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Within | 130 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Within | 123 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Within | 123 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Above | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Below | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Above | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 7 | Unknown | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 182 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Above | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Above | 4 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Unknown | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Within | 129 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Within | 128 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Within | 127 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Within | 130 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Below | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 21 | Above | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Within | 118 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 182 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | NEU, Day 42 | Within | 123 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 7 | Below | 5 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 42 | Below | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 21 | Below | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Above | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 28 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Within | 108 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Unknown | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 42 | Unknown | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Within | 129 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 21 | Within | 127 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Within | 126 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 21 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 42 | Below | 8 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 42 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 21 | Within | 127 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 28 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Within | 130 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 21 | Within | 125 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Above | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 182 | Above | 5 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Within | 128 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | LYM, Day 7 | Below | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 28 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Within | 108 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Above | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Below | 19 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Within | 130 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Within | 127 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Above | 5 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Within | 130 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | MON, Day 28 | Unknown | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 28 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 7 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 182 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Unknown | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 42 | Within | 122 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Within | 130 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Within | 121 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 42 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 182 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 42 | Above | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Above | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Within | 130 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 42 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL/CD, Day 21 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 21 | Below | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 7 | Above | 6 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 182 | Above | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Within | 128 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 7 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Within | 128 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 7 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Above | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Within | 119 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Above | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Within | 126 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | RBC, Day 28 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 182 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Within | 124 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BUN, Day 28 | Above | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 182 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Below | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Within | 122 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 42 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 182 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 42 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Above | 4 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 182 | Unknown | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | WBC, Day 28 | Unknown | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Within | 130 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Above | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 182 | Above | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Above | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 28 | Above | 5 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 21 | Within | 129 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Within | 122 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 7 | Above | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 28 | Above | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BAS, Day 42 | Within | 128 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 7 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Within | 121 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 42 | Unknown | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Within | 128 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | BIL, Day 7 | Within | 129 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 28 | Within | 125 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 182 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HgB, Day 28 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 21 | Within | 119 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AST, Day 7 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 28 | Within | 124 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | HEM, Day 42 | Within | 121 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | ALT, Day 21 | Above | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 28 | Unknown | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | AP, Day 7 | Below | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | CREA, Day 21 | Above | 4 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | PLA, Day 21 | Below | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Abnormal Biochemical and Haematological Levels | EOS, Day 28 | Unknown | 1 Participants |
Secondary
Number of Subjects With Any and Grade 3 Solicited General Symptoms
Assessed solicited general symptoms were fatigue, fever \[defined as axillary temperature equal to or above (≥) 38 degrees Celsius (°C)\], headache, joint pain at other location, muscle aches, shivering and sweating. Any = occurrence of the symptom regardless of intensity grade or relationship to vaccination. Grade 3 symptom = symptom that prevented normal everyday activities as assessed by inability to attend/do work or school, or required intervention of a physician/healthcare provider. Grade 3 fever = fever ≥ 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination. Results were tabulated for subjects in GSK2340273A F2\_1D Group, who were older than 60 years of age (\>60y).
Time frame: During the 7-day (Days 0-6) post-Dose 3 vaccination period, for subjects > 60 years of age
Population: The analysis was performed on the Total Vaccinated cohort, which included all subjects who received at least 1 study vaccination and had their symptom sheets filled in. This analysis focused on subjects who received an additional dose of GSK2340273A F2 vaccine from GSK2340273A F2\_1D Group.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited General Symptoms | Any Fatigue | 6 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited General Symptoms | Grade 3 Fatigue | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited General Symptoms | Related Fatigue | 6 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited General Symptoms | Any Headache | 6 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited General Symptoms | Grade 3 Headache | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited General Symptoms | Related Headache | 4 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited General Symptoms | Any Joint pain at other location | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited General Symptoms | Grade 3 Joint pain at other location | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited General Symptoms | Related Joint pain at other location | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited General Symptoms | Any Muscle aches | 4 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited General Symptoms | Grade 3 Muscle aches | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited General Symptoms | Related Muscle aches | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited General Symptoms | Any Shivering | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited General Symptoms | Grade 3 Temperature | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited General Symptoms | Grade 3 Shivering | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited General Symptoms | Related Shivering | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited General Symptoms | Any Sweating | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited General Symptoms | Grade 3 Sweating | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited General Symptoms | Related Sweating | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited General Symptoms | Any Temperature | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited General Symptoms | Related Temperature | 0 Participants |
Secondary
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activities as assessed by inability to attend/do work or school. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses, for subjects between 18-64 years of age
Population: The analysis was performed on the Total Vaccinated cohort, which included all subjects who received at least 1 study vaccination and had their symptom sheets filled in.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 2 | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Across doses | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Across doses | 7 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Across doses | 6 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 1 | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 1 | 4 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 2 | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 2 | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 1 | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Across doses | 6 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Across doses | 81 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Across doses | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 1 | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 2 | 5 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 2 | 68 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 2 | 5 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 1 | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 1 | 74 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 1 | 39 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 2 | 3 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 2 | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Across doses | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Across doses | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 2 | 37 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Across doses | 5 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 1 | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 2 | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Across doses | 3 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 2 | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 1 | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 2 | 3 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Across doses | 43 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Across doses | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 1 | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 1 | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 1 | 3 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 2 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Across doses | 36 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 1 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Across doses | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 1 | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 1 | 35 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 1 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Across doses | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 1 | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Across doses | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Across doses | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 2 | 4 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 2 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Across doses | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 2 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 2 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 1 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 2 | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 2 | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 1 | 9 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 2 | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Across doses | 80 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Across doses | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 1 | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Across doses | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 2 | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 2 | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 1 | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 1 | 7 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Across doses | 9 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 1 | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 1 | 80 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 2 | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Across doses | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 2 | 12 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Across doses | 7 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 1 | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 1 | 25 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 1 | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 1 | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 1 | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 1 | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 2 | 15 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 2 | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 2 | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 2 | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 2 | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Across doses | 28 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 2 | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Across doses | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Across doses | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Across doses | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Across doses | 3 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Across doses | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Across doses | 15 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 2 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Across doses | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 1 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Across doses | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Across doses | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 1 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 2 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 2 | 7 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Across doses | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 1 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 2 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 1 | 10 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 2 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 2 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 1 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Across doses | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 1 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Across doses | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 1 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 2 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 2 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 2 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 2 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 2 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Across doses | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 2 | 4 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 1 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Across doses | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 1 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 1 | 11 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Across doses | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 1 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 1 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Across doses | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Across doses | 13 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 1 | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Across doses | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Across doses | 23 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 1 | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Across doses | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 1 | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 2 | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 1 | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 2 | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Across doses | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Across doses | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 1 | 16 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 2 | 10 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 2 | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Across doses | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 1 | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 2 | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 2 | 0 Participants |
Secondary
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activities as assessed by inability to attend/do work or school. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. Results were tabulated for subjects in GSK2340273A F2\_1D Group, who were older than 60 years of age (\>60y).
Time frame: During the 7-day (Days 0-6) post-Dose 3 vaccination period, for subjects > 60 years of age
Population: The analysis was performed on the Total Vaccinated cohort, which included all subjects who received at least 1 study vaccination and had their symptom sheets filled in. This analysis focused on subjects who received an additional dose of GSK2340273A F2 vaccine from GSK2340273A F2\_1D Group.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain | 6 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling | 0 Participants |
Secondary
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activities as assessed by inability to attend/do work or school. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
Time frame: During the 7-day (Day 0-6) post-vaccination period following each dose and across doses, for subjects > 64 years of age
Population: The analysis was performed on the Total Vaccinated cohort, which included all subjects who received at least 1 study vaccination and had their symptom sheets filled in.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 2 | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 2 | 63 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 1 | 9 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 1 | 73 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 1 | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Across doses | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Across doses | 13 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Across doses | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 1 | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 1 | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Across doses | 16 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Across doses | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Across doses | 87 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 1 | 6 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 2 | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 2 | 8 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 2 | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 2 | 12 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Across doses | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 1 | 28 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 1 | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 1 | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 1 | 3 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 1 | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 2 | 23 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 2 | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 2 | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 2 | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 2 | 3 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 2 | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Across doses | 33 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Across doses | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Across doses | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Across doses | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Across doses | 5 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 1 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 2 | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Across doses | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 1 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Across doses | 3 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Across doses | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 2 | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 1 | 21 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 1 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 2 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 2 | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 2 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Across doses | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Across doses | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 2 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 1 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 1 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Across doses | 21 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 1 | 3 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 2 | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Across doses | 7 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 1 | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Across doses | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 2 | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 1 | 9 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 2 | 4 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Across doses | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 2 | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 1 | 75 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Across doses | 11 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 1 | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 2 | 3 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 2 | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 1 | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Across doses | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 1 | 6 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Across doses | 76 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 2 | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 1 | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 2 | 3 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Across doses | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 2 | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Across doses | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 1 | 4 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Across doses | 19 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 2 | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Across doses | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 2 | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Across doses | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Across doses | 4 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 1 | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 2 | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 1 | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 1 | 17 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 1 | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 2 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 1 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 2 | 6 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 1 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 2 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 2 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 2 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 2 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Across doses | 10 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Across doses | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 1 | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Across doses | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Across doses | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Across doses | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 1 | 4 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Across doses | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 1 | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 1 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 2 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 1 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 2 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 1 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Across doses | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 2 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 2 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 1 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 1 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Across doses | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Across doses | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 1 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Across doses | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 2 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Across doses | 7 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 2 | 3 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Across doses | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 1 | 4 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Across doses | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 2 | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 2 | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Across doses | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 1 | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 2 | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 2 | 7 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Across doses | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness, Dose 2 | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 1 | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Dose 2 | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Dose 1 | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness, Dose 1 | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling, Dose 1 | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain, Across doses | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Across doses | 15 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling, Across doses | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain, Dose 1 | 10 Participants |
Secondary
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
Assessed solicited general symptoms were fatigue, fever \[defined as axillary temperature equal to or above (≥) 38 degrees Celsius (°C)\], headache, joint pain at other location, muscle aches, shivering and sweating. Any = occurrence of the symptom regardless of intensity grade or relationship to vaccination. Grade 3 symptom = symptom that prevented normal everyday activities as assessed by inability to attend/do work or school, or required intervention of a physician/healthcare provider. Grade 3 fever = fever ≥ 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
Time frame: During the 7-day (Day 0-6) post-vaccination period following each dose and across doses, for subjects between 18-64 years of age
Population: The analysis was performed on the Total Vaccinated cohort, which included all subjects who received at least 1 study vaccination and had their symptom sheets filled in.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 2 | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Across doses | 5 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 1 | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Dose 2 | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 1 | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Across doses | 37 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 1 | 6 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 1 | 9 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 1 | 27 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Dose 2 | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Across doses | 5 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Across doses | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Dose 2 | 27 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 1 | 33 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Across doses | 6 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Across doses | 13 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 1 | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 2 | 9 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Dose 2 | 6 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Dose 2 | 29 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Across doses | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 1 | 28 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Dose 2 | 18 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Across doses | 14 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Dose 1 | 15 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 2 | 11 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Across doses | 18 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Dose 2 | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Across doses | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Dose 1 | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Dose 2 | 18 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 1 | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Across doses | 21 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Across doses | 40 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 2 | 20 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Dose 1 | 14 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Across doses | 7 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 2 | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Across doses | 42 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 2 | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Across doses | 25 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 2 | 23 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Dose 1 | 32 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 2 | 22 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Across doses | 4 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 2 | 8 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 2 | 4 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 1 | 5 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Across doses | 26 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 2 | 26 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Dose 1 | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Across doses | 38 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Across doses | 4 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Dose 1 | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Dose 2 | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Dose 1 | 29 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 2 | 13 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Across doses | 43 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Dose 1 | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Across doses | 35 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Dose 1 | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 1 | 10 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 1 | 27 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Across doses | 22 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Across doses | 3 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Across doses | 21 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 1 | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Across doses | 11 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Across doses | 24 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 1 | 3 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 2 | 12 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Dose 1 | 19 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Dose 2 | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 1 | 15 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 1 | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 2 | 16 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Dose 1 | 10 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Dose 2 | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 1 | 7 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 1 | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Across doses | 4 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Dose 2 | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 2 | 2 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Across doses | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Dose 1 | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Dose 2 | 12 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Across doses | 22 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Across doses | 19 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 1 | 13 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 2 | 2 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Across doses | 2 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 2 | 5 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Across doses | 4 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 2 | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Dose 2 | 2 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 1 | 15 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 1 | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Across doses | 11 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 1 | 3 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Across doses | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Dose 2 | 13 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 2 | 15 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Across doses | 3 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 2 | 13 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 1 | 13 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 2 | 3 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Dose 2 | 4 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Dose 1 | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Across doses | 4 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Dose 1 | 19 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Dose 2 | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 2 | 2 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Dose 1 | 10 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Dose 1 | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Across doses | 7 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Across doses | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Across doses | 2 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Across doses | 2 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 2 | 3 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Across doses | 22 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Dose 1 | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Dose 1 | 2 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Dose 2 | 6 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 1 | 7 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 2 | 2 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Across doses | 8 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 2 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 1 | 8 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 1 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 1 | 5 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 1 | 15 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 1 | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 1 | 8 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Dose 1 | 5 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Dose 1 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Dose 1 | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 2 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Dose 1 | 7 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 2 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Dose 1 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Dose 1 | 6 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Dose 2 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 1 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Dose 2 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 1 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Dose 2 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 1 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 1 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Across doses | 9 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 1 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Across doses | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 1 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Dose 1 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Across doses | 7 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Dose 1 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Across doses | 15 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Dose 1 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Across doses | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Across doses | 8 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 2 | 4 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Across doses | 5 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 2 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Across doses | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 2 | 3 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 2 | 3 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Across doses | 3 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 2 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Across doses | 8 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Across doses | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 2 | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Across doses | 8 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Across doses | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Dose 2 | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Across doses | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Across doses | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Dose 2 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Across doses | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Dose 2 | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Dose 2 | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Across doses | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Dose 2 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Across doses | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Across doses | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Dose 2 | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Across doses | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Across doses | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 2 | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 2 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 2 | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Dose 1 | 15 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 2 | 3 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Dose 2 | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 2 | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 2 | 14 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Across doses | 26 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Dose 1 | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 2 | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 1 | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Across doses | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Across doses | 26 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Dose 1 | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 2 | 13 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 2 | 11 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 2 | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Across doses | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 2 | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 1 | 20 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Across doses | 17 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 1 | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 1 | 21 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Dose 2 | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Dose 1 | 33 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Across doses | 6 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 1 | 6 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Dose 2 | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 1 | 32 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Dose 2 | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 2 | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Across doses | 27 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Across doses | 37 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Across doses | 8 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 1 | 26 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 2 | 11 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Dose 2 | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Across doses | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Across doses | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Dose 1 | 12 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 1 | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Across doses | 33 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Dose 2 | 7 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 1 | 3 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 2 | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Across doses | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 1 | 8 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Dose 2 | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 1 | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 2 | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 1 | 4 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Across doses | 34 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Across doses | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Across doses | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Dose 1 | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Dose 1 | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Across doses | 11 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Across doses | 5 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Dose 2 | 6 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Across doses | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Dose 1 | 26 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Dose 1 | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Across doses | 14 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Across doses | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Dose 2 | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Dose 1 | 15 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Dose 1 | 13 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Across doses | 9 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Across doses | 10 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Dose 2 | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Across doses | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 1 | 18 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Dose 2 | 7 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Across doses | 12 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Across doses | 34 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 1 | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Across doses | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Dose 2 | 12 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 1 | 7 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Dose 1 | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 1 | 5 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Dose 1 | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Across doses | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Dose 2 | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Across doses | 3 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 2 | 5 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Across doses | 24 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Dose 2 | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 2 | 15 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Across doses | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 1 | 7 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Across doses | 16 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 1 | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Dose 2 | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 2 | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Across doses | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 1 | 9 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 2 | 13 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Across doses | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 1 | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 2 | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Across doses | 12 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Across doses | 26 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Dose 2 | 10 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 2 | 22 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 1 | 20 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Dose 1 | 3 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 2 | 8 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 2 | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Across doses | 21 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 2 | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Dose 1 | 10 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Across doses | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Across doses | 30 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Dose 1 | 11 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Across doses | 4 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Dose 1 | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Across doses | 15 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 2 | 6 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 2 | 15 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 1 | 3 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 2 | 6 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Across doses | 12 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Dose 2 | 9 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 1 | 26 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Dose 1 | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Dose 2 | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 1 | 24 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Across doses | 17 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 2 | 17 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Across doses | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Dose 1 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 1 | 11 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Dose 1 | 3 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 2 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Across doses | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Dose 1 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Dose 2 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Across doses | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Dose 2 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 2 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Across doses | 14 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Dose 1 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 2 | 4 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Dose 2 | 7 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Across doses | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 1 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 1 | 12 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 2 | 4 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Across doses | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Across doses | 23 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 2 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Across doses | 5 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Across doses | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Dose 1 | 8 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Dose 1 | 4 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Across doses | 5 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Dose 1 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Dose 1 | 10 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Across doses | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 2 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Across doses | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Dose 2 | 7 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Across doses | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Across doses | 7 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 1 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Dose 2 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 2 | 10 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 1 | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Across doses | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 2 | 10 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Dose 2 | 4 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Across doses | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Across doses | 18 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 1 | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Across doses | 22 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 1 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 2 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Dose 1 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Across doses | 13 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 1 | 13 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 2 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 1 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Dose 2 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 1 | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 1 | 15 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Across doses | 6 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Dose 2 | 4 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Dose 2 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 2 | 16 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 1 | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 1 | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Across doses | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 1 | 3 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Across doses | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Dose 1 | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Dose 1 | 3 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Across doses | 9 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Dose 1 | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Across doses | 18 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Dose 1 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 1 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Across doses | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Dose 1 | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 2 | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Across doses | 12 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 2 | 7 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Dose 1 | 4 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Across doses | 6 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 2 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Across doses | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 2 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 2 | 6 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Across doses | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Across doses | 6 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 2 | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 2 | 12 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Dose 1 | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Across doses | 8 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 2 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Dose 1 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Across doses | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 2 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Across doses | 7 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 2 | 8 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Across doses | 3 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Dose 2 | 5 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Dose 1 | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Across doses | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Across doses | 3 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Dose 2 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 1 | 9 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 2 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Dose 2 | 5 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Across doses | 6 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 1 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 1 | 8 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Dose 2 | 5 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Across doses | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 1 | 11 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Across doses | 3 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Dose 2 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 1 | 5 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Across doses | 3 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 1 | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Dose 2 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 2 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 1 | 3 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Dose 2 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 1 | 5 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 1 | 3 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Dose 2 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Dose 2 | 5 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Across doses | 12 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Across doses | 7 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Dose 1 | 10 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Across doses | 11 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 2 | 13 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Across doses | 15 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Dose 1 | 9 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 2 | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Dose 2 | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 1 | 13 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Across doses | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Dose 1 | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 1 | 8 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 1 | 7 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Across doses | 4 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 2 | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Across doses | 24 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 2 | 18 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 2 | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Across doses | 8 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Dose 1 | 6 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 2 | 8 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Across doses | 25 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Across doses | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 1 | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Dose 2 | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Dose 2 | 8 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Across doses | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 2 | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Across doses | 13 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Across doses | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 2 | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 2 | 15 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Dose 1 | 17 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Across doses | 28 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Dose 1 | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 1 | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Across doses | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Dose 2 | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 1 | 4 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 2 | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Across doses | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Dose 2 | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 2 | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Across doses | 36 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Dose 1 | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 1 | 9 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 1 | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Dose 2 | 13 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 1 | 20 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 1 | 27 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 1 | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Dose 2 | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Dose 1 | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Across doses | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Across doses | 18 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 2 | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Across doses | 9 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Dose 2 | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Across doses | 6 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 1 | 22 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Across doses | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Dose 1 | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Dose 2 | 6 Participants |
Secondary
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
Assessed solicited general symptoms were fatigue, fever \[defined as axillary temperature equal to or above (≥) 38 degrees Celsius (°C)\], headache, joint pain at other location, muscle aches, shivering and sweating. Any = occurrence of the symptom regardless of intensity grade or relationship to vaccination. Grade 3 symptom = symptom that prevented normal everyday activities as assessed by inability to attend/do work or school, or required intervention of a physician/healthcare provider. Grade 3 fever = fever ≥ 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
Time frame: During the 7-day (Day 0-6) post-vaccination period following each dose and across doses, for subjects > 64 years of age
Population: The analysis was performed on the Total Vaccinated cohort, which included all subjects who received at least 1 study vaccination and had their symptom sheets filled in.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Across doses | 8 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Dose 2 | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Dose 2 | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Dose 2 | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 2 | 5 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 2 | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Dose 2 | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Dose 2 | 30 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Across doses | 10 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Dose 2 | 15 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Across doses | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Across doses | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Across doses | 13 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Across doses | 35 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Across doses | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Across doses | 41 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Across doses | 20 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Across doses | 29 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Across doses | 22 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 2 | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Across doses | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Across doses | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Across doses | 34 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Across doses | 36 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Across doses | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 1 | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 2 | 28 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Across doses | 7 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 2 | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 2 | 29 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 2 | 6 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Dose 1 | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Dose 1 | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 2 | 7 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 1 | 4 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Across doses | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Dose 1 | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 2 | 1 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 1 | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 2 | 8 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 1 | 6 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 1 | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Dose 2 | 27 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Dose 1 | 22 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 1 | 3 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 2 | 20 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 2 | 23 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Dose 1 | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Dose 1 | 25 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Dose 1 | 10 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 1 | 23 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Dose 1 | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Dose 1 | 11 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Dose 2 | 16 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Across doses | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 1 | 17 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 1 | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 1 | 20 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 1 | 21 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 1 | 2 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Across doses | 0 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Across doses | 38 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Dose 2 | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Dose 2 | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 2 | 7 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 2 | 2 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 2 | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 1 | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 1 | 3 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 2 | 7 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Dose 2 | 12 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Dose 2 | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Dose 2 | 17 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Dose 2 | 12 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Dose 2 | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 2 | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 2 | 2 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Dose 2 | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Dose 2 | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Across doses | 18 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Across doses | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 1 | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 1 | 8 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 1 | 11 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 1 | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 1 | 7 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Dose 1 | 7 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Dose 1 | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 1 | 12 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Dose 1 | 5 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Dose 1 | 11 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Dose 1 | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 1 | 2 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Dose 1 | 9 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Dose 2 | 17 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 1 | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 1 | 5 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 2 | 5 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 1 | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 2 | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Dose 1 | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 2 | 5 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Dose 1 | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Dose 1 | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 2 | 12 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 2 | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 2 | 12 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Across doses | 1 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Across doses | 15 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Across doses | 13 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Across doses | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Across doses | 14 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Across doses | 10 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Across doses | 13 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Across doses | 18 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Across doses | 2 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Across doses | 18 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Across doses | 9 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Across doses | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Across doses | 7 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Across doses | 4 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Across doses | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Across doses | 3 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Across doses | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Across doses | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Across doses | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Dose 2 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Dose 2 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 2 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Dose 1 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 1 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 2 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Across doses | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 1 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Dose 1 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 1 | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 1 | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 2 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Dose 2 | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 1 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Dose 2 | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Dose 2 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 1 | 4 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 2 | 5 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Across doses | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Across doses | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Across doses | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 1 | 5 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 2 | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Across doses | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 1 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Across doses | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Across doses | 3 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Dose 2 | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 1 | 4 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Across doses | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Across doses | 6 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Across doses | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Dose 1 | 4 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Across doses | 4 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Across doses | 6 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Dose 1 | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Across doses | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Across doses | 5 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Across doses | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 1 | 5 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Dose 1 | 3 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Dose 2 | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Across doses | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 2 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Across doses | 6 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Dose 1 | 4 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Across doses | 9 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 2 | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Across doses | 4 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Dose 1 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 2 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Across doses | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 1 | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 2 | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 2 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Dose 2 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 1 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Dose 1 | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 2 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 2 | 3 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Across doses | 1 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Dose 1 | 0 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Dose 2 | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Dose 2 | 8 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Dose 1 | 11 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 2 | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 1 | 3 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Across doses | 31 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Across doses | 4 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Dose 1 | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Dose 2 | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 2 | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Across doses | 17 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 1 | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 2 | 15 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Across doses | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 2 | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Dose 1 | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 1 | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Dose 2 | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Across doses | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Across doses | 27 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Dose 1 | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 1 | 3 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Across doses | 3 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 1 | 4 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Dose 2 | 11 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Dose 2 | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 2 | 2 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Across doses | 3 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Dose 2 | 9 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Across doses | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Across doses | 18 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 1 | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 1 | 4 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 1 | 24 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Dose 1 | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Across doses | 5 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 1 | 27 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Across doses | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 2 | 9 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Across doses | 19 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Across doses | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 1 | 14 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Dose 2 | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 2 | 10 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Across doses | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Across doses | 5 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Dose 2 | 12 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Dose 1 | 10 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Dose 1 | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 1 | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Dose 1 | 25 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 2 | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Across doses | 27 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Dose 2 | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Across doses | 23 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 2 | 12 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 2 | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 1 | 12 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Across doses | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Across doses | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 2 | 0 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Across doses | 31 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 2 | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Dose 1 | 29 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Across doses | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Dose 2 | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Across doses | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 1 | 16 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Across doses | 28 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 1 | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Across doses | 7 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 1 | 14 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Dose 2 | 9 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 1 | 18 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 1 | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 1 | 12 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Dose 1 | 7 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Dose 1 | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Dose 1 | 6 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 2 | 4 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Across doses | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Dose 1 | 16 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Dose 1 | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Dose 2 | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Dose 1 | 11 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Dose 2 | 8 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 1 | 4 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 2 | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Across doses | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 1 | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 1 | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 2 | 6 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Across doses | 7 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 1 | 4 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 2 | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Dose 1 | 4 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Dose 1 | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 2 | 5 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 1 | 4 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Dose 1 | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 1 | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 2 | 17 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 2 | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Across doses | 7 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Across doses | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Across doses | 21 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Across doses | 25 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 2 | 11 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Across doses | 15 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Across doses | 15 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Across doses | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 2 | 3 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Across doses | 9 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Across doses | 23 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 2 | 10 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Across doses | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Across doses | 17 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Across doses | 10 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Across doses | 1 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Dose 2 | 4 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Dose 2 | 13 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Across doses | 7 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 2 | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Dose 2 | 0 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 2 | 3 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Dose 2 | 4 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Dose 2 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Dose 1 | 3 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Across doses | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Dose 1 | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Across doses | 4 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 2 | 4 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Across doses | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 1 | 5 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Dose 2 | 4 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 2 | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Across doses | 6 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 1 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Across doses | 4 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 2 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Across doses | 9 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Across doses | 5 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Across doses | 8 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Across doses | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Dose 2 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Across doses | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Dose 2 | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Dose 1 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 1 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 2 | 3 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 1 | 3 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Dose 2 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Dose 1 | 3 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 2 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Across doses | 4 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 2 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Across doses | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 2 | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Across doses | 10 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Across doses | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 1 | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 2 | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Dose 1 | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Dose 1 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Across doses | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 1 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Across doses | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Dose 2 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 1 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 1 | 5 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Across doses | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 2 | 3 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Across doses | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 1 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Across doses | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Dose 2 | 4 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 1 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Across doses | 7 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Dose 1 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Dose 2 | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 2 | 3 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Dose 2 | 2 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Dose 1 | 6 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 1 | 5 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 2 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Across doses | 6 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Dose 1 | 5 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 1 | 3 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Dose 2 | 0 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 2 | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Dose 1 | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 1 | 11 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 2 | 6 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Dose 1 | 5 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Dose 1 | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 2 | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 2 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Dose 2 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 2 | 8 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 2 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Dose 1 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 2 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Across doses | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Across doses | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Across doses | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 1 | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Across doses | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Across doses | 11 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Dose 1 | 7 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Dose 2 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Across doses | 11 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Dose 1 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 2 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Across doses | 11 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Across doses | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Across doses | 3 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Dose 1 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Across doses | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 2 | 7 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 2 | 7 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Dose 1 | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Across doses | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Across doses | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Across doses | 11 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 1 | 6 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Across doses | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Across doses | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 1 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Dose 2 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Across doses | 8 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Across doses | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Across doses | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 1 | 6 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Dose 2 | 3 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Across doses | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 1 | 7 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Across doses | 17 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Dose 2 | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 1 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Dose 2 | 5 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Dose 2 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Dose 2 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 2 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 2 | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 1 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 1 | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Across doses | 1 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Dose 2 | 3 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 1 | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 2 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Dose 1 | 2 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 1 | 0 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 1 | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 2 | 12 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Across doses | 13 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 1 | 11 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Dose 2 | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 1 | 6 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Dose 1 | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Across doses | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Across doses | 17 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Across doses | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 1 | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Dose 1 | 4 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Across doses | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Across doses | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 1 | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Dose 2 | 5 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Across doses | 15 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 2 | 11 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Dose 2 | 4 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Dose 2 | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Dose 1 | 14 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Across doses | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Dose 2 | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Dose 1 | 4 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Dose 2 | 5 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Dose 2 | 8 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 2 | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 2 | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Shivering, Dose 1 | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Dose 2 | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Across doses | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Across doses | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 2 | 6 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Sweating, Dose 1 | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 1 | 10 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache, Dose 2 | 7 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue, Dose 2 | 8 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Temperature, Dose 1 | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Muscle aches, Across doses | 9 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Dose 2 | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Joint pain at other location, Across doses | 6 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 2 | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Dose 1 | 6 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Shivering, Across doses | 11 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Across doses | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Dose 1 | 7 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Across doses | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Sweating, Across doses | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue, Across doses | 20 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache, Dose 1 | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Dose 1 | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 1 | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Joint pain at other location, Across doses | 9 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue, Dose 2 | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Across doses | 7 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Sweating, Dose 2 | 1 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Temperature, Across doses | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Dose 2 | 7 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache, Dose 1 | 11 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Temperature, Dose 2 | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Joint pain at other location, Dose 1 | 0 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Muscle aches, Dose 1 | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Shivering, Across doses | 13 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Muscle aches, Dose 1 | 0 Participants |
Secondary
Number of Subjects With Any Medically-attended Adverse Events (MAEs)
MAEs were defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any was defined as the occurrence of any MAE regardless of intensity grade or relation to vaccination. Results were tabulated for subjects aged between 18 and 64 years and older (\>64y).
Time frame: Days 0 to 385
Population: The analysis was performed on the Total Vaccinated cohort, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK2340274A F1_2D Group | Number of Subjects With Any Medically-attended Adverse Events (MAEs) | Any MAEs, 18-64y | 49 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any Medically-attended Adverse Events (MAEs) | Any MAEs, >64y | 60 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any Medically-attended Adverse Events (MAEs) | Any MAEs, 18-64y | 24 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any Medically-attended Adverse Events (MAEs) | Any MAEs, >64y | 37 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any Medically-attended Adverse Events (MAEs) | Any MAEs, 18-64y | 14 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any Medically-attended Adverse Events (MAEs) | Any MAEs, >64y | 39 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any Medically-attended Adverse Events (MAEs) | Any MAEs, 18-64y | 32 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any Medically-attended Adverse Events (MAEs) | Any MAEs, >64y | 67 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any Medically-attended Adverse Events (MAEs) | Any MAEs, 18-64y | 38 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any Medically-attended Adverse Events (MAEs) | Any MAEs, >64y | 62 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any Medically-attended Adverse Events (MAEs) | Any MAEs, 18-64y | 23 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any Medically-attended Adverse Events (MAEs) | Any MAEs, >64y | 35 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any Medically-attended Adverse Events (MAEs) | Any MAEs, >64y | 40 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any Medically-attended Adverse Events (MAEs) | Any MAEs, 18-64y | 23 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any Medically-attended Adverse Events (MAEs) | Any MAEs, 18-64y | 36 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any Medically-attended Adverse Events (MAEs) | Any MAEs, >64y | 59 Participants |
Secondary
Number of Subjects With Any Unsolicited Adverse Events (AEs)
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Results were tabulated for subjects aged between 18-64 years and older (\>64y).
Time frame: Within the 84-day (Days 0-83) post-vaccination period
Population: The analysis was performed on the Total Vaccinated cohort, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK2340274A F1_2D Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) | Any AE(s), 18-64y | 51 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) | Any AE(s), > 64y | 66 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) | Any AE(s), 18-64y | 29 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) | Any AE(s), > 64y | 32 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) | Any AE(s), 18-64y | 18 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) | Any AE(s), > 64y | 32 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) | Any AE(s), 18-64y | 46 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) | Any AE(s), > 64y | 62 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) | Any AE(s), 18-64y | 36 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) | Any AE(s), > 64y | 61 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) | Any AE(s), 18-64y | 26 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) | Any AE(s), > 64y | 30 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) | Any AE(s), > 64y | 35 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) | Any AE(s), 18-64y | 27 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) | Any AE(s), 18-64y | 44 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) | Any AE(s), > 64y | 64 Participants |
Secondary
Number of Subjects With Any Unsolicited Adverse Events (AEs)
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
Time frame: Within the 42-day (Days 0-41) post-vaccination period
Population: The analysis was performed on the Total Vaccinated cohort, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| GSK2340274A F1_2D Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) | 97 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) | 55 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) | 38 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) | 93 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) | 82 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) | 43 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) | 55 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) | 86 Participants |
Secondary
Number of Subjects With Serious Adverse Events (SAEs)
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Results were tabulated for subjects aged between 18-64 years and older (\>64y).
Time frame: During the entire study period (from Day 0 to Day 385)
Population: The analysis was performed on the Total Vaccinated cohort, which included all subjects who received at least 1 study vaccination.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK2340274A F1_2D Group | Number of Subjects With Serious Adverse Events (SAEs) | Any SAE(s), 18-64y | 7 Participants |
| GSK2340274A F1_2D Group | Number of Subjects With Serious Adverse Events (SAEs) | Any SAE(s), > 64y | 12 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Serious Adverse Events (SAEs) | Any SAE(s), 18-64y | 0 Participants |
| GSK2340274A F2_2D Group | Number of Subjects With Serious Adverse Events (SAEs) | Any SAE(s), > 64y | 5 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Serious Adverse Events (SAEs) | Any SAE(s), 18-64y | 2 Participants |
| GSK2340274A F2_1D Group | Number of Subjects With Serious Adverse Events (SAEs) | Any SAE(s), > 64y | 4 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Serious Adverse Events (SAEs) | Any SAE(s), 18-64y | 1 Participants |
| GSK2340274A F1_1D Group | Number of Subjects With Serious Adverse Events (SAEs) | Any SAE(s), > 64y | 7 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Serious Adverse Events (SAEs) | Any SAE(s), 18-64y | 2 Participants |
| GSK2340273A F1_1D Group | Number of Subjects With Serious Adverse Events (SAEs) | Any SAE(s), > 64y | 6 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Serious Adverse Events (SAEs) | Any SAE(s), 18-64y | 1 Participants |
| GSK2340273A F2_2D Group | Number of Subjects With Serious Adverse Events (SAEs) | Any SAE(s), > 64y | 4 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Serious Adverse Events (SAEs) | Any SAE(s), > 64y | 7 Participants |
| GSK2340273A F2_1D Group | Number of Subjects With Serious Adverse Events (SAEs) | Any SAE(s), 18-64y | 2 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Serious Adverse Events (SAEs) | Any SAE(s), 18-64y | 3 Participants |
| GSK2340273A F3_2D Group | Number of Subjects With Serious Adverse Events (SAEs) | Any SAE(s), > 64y | 8 Participants |
Secondary
Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain
SCF was defined as the fold increase in serum HI geometric mean ratio (mean\[log10(POST/PRE)\]) vaccination compared to Day 21. The flu strain assessed was Flu A/CAL/7/09 and results were tabulated for subjects between 18-60 years of age and older (\> 60y) and for subjects between 18-64 years old and \> 64 years.
Time frame: At Day 21
Population: The analysis was performed on the ATP cohort for immunogenicity, which included all subjects who received the vaccine/ placebo doses on both Days 0 and 21 and from whom assay results for antibodies against A/California-like HA antigen for blood samples taken were available.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK2340274A F1_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 64y | 11.1 Fold increase |
| GSK2340274A F1_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 60y | 11.8 Fold increase |
| GSK2340274A F1_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-64y | 28.8 Fold increase |
| GSK2340274A F1_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-60y | 29.9 Fold increase |
| GSK2340274A F2_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-60y | 20.1 Fold increase |
| GSK2340274A F2_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-64y | 18.3 Fold increase |
| GSK2340274A F2_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 60y | 8.3 Fold increase |
| GSK2340274A F2_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 64y | 8.2 Fold increase |
| GSK2340274A F2_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 60y | 6.7 Fold increase |
| GSK2340274A F2_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-60y | 17.0 Fold increase |
| GSK2340274A F2_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 64y | 6.5 Fold increase |
| GSK2340274A F2_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-64y | 15.8 Fold increase |
| GSK2340274A F1_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 64y | 9.6 Fold increase |
| GSK2340274A F1_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-60y | 30.2 Fold increase |
| GSK2340274A F1_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 60y | 9.9 Fold increase |
| GSK2340274A F1_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-64y | 29.6 Fold increase |
| GSK2340273A F1_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 64y | 5.7 Fold increase |
| GSK2340273A F1_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-64y | 10.3 Fold increase |
| GSK2340273A F1_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 60y | 6.1 Fold increase |
| GSK2340273A F1_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-60y | 10.0 Fold increase |
| GSK2340273A F2_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 64y | 4.5 Fold increase |
| GSK2340273A F2_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 60y | 4.8 Fold increase |
| GSK2340273A F2_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-64y | 16.4 Fold increase |
| GSK2340273A F2_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-60y | 15.9 Fold increase |
| GSK2340273A F2_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-60y | 21.1 Fold increase |
| GSK2340273A F2_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 60y | 3.8 Fold increase |
| GSK2340273A F2_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 64y | 3.5 Fold increase |
| GSK2340273A F2_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-64y | 20.7 Fold increase |
| GSK2340273A F3_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 64y | 3.7 Fold increase |
| GSK2340273A F3_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-60y | 9.1 Fold increase |
| GSK2340273A F3_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 60y | 3.8 Fold increase |
| GSK2340273A F3_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-64y | 8.9 Fold increase |
Secondary
Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain
SCF was defined as the fold increase in serum HI geometric mean ratio (mean\[log10(POST/PRE)\]) vaccination compared to Day 21. The flu strain assessed was Flu A/CAL/7/09 and results were tabulated for subjects between 18-60 years of age and older (\> 60y) and for subjects between 18-64 years old and \> 64 years.
Time frame: At Day 42
Population: The analysis was performed on the ATP cohort for immunogenicity, which included all subjects who received the vaccine/ placebo doses on both Days 0 and 21 and from whom assay results for antibodies against A/California-like HA antigen for blood samples taken were available.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK2340274A F1_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 64 y | 21.6 Fold increase |
| GSK2340274A F1_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-64 y | 35.4 Fold increase |
| GSK2340274A F1_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 60 y | 21.1 Fold increase |
| GSK2340274A F1_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-60 y | 38.3 Fold increase |
| GSK2340274A F2_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 64 y | 14.0 Fold increase |
| GSK2340274A F2_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-64 y | 30.5 Fold increase |
| GSK2340274A F2_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 60 y | 14.2 Fold increase |
| GSK2340274A F2_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-60 y | 32.9 Fold increase |
| GSK2340274A F2_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-64 y | 11.9 Fold increase |
| GSK2340274A F2_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 64 y | 5.7 Fold increase |
| GSK2340274A F2_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 60 y | 5.8 Fold increase |
| GSK2340274A F2_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-60 y | 12.8 Fold increase |
| GSK2340274A F1_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 64 y | 8.0 Fold increase |
| GSK2340274A F1_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-64 y | 20.8 Fold increase |
| GSK2340274A F1_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 60 y | 8.1 Fold increase |
| GSK2340274A F1_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-60 y | 22.4 Fold increase |
| GSK2340273A F1_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-64 y | 6.5 Fold increase |
| GSK2340273A F1_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 64 y | 6.0 Fold increase |
| GSK2340273A F1_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-60 y | 6.6 Fold increase |
| GSK2340273A F1_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 60 y | 6.0 Fold increase |
| GSK2340273A F2_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-60 y | 18.7 Fold increase |
| GSK2340273A F2_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-64 y | 19.1 Fold increase |
| GSK2340273A F2_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 60 y | 5.6 Fold increase |
| GSK2340273A F2_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 64 y | 5.3 Fold increase |
| GSK2340273A F2_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 64 y | 2.9 Fold increase |
| GSK2340273A F2_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 60 y | 3.2 Fold increase |
| GSK2340273A F2_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-64 y | 18.6 Fold increase |
| GSK2340273A F2_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-60 y | 18.5 Fold increase |
| GSK2340273A F3_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 64 y | 5.0 Fold increase |
| GSK2340273A F3_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-64 y | 8.7 Fold increase |
| GSK2340273A F3_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 60 y | 5.1 Fold increase |
| GSK2340273A F3_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-60 y | 8.9 Fold increase |
Secondary
Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain
SCF was defined as the fold increase in serum HI geometric mean ratio (mean\[log10(POST/PRE)\]) vaccination compared to Day 21. The flu strain assessed was Flu A/CAL/7/09 and results were tabulated for subjects between 18-60 years of age and older (\> 60y) and for subjects between 18-64 years old and \> 64 years.
Time frame: At Day 182
Population: The analysis was performed on the ATP cohort for immunogenicity, which included all subjects who received the vaccine/ placebo doses on both Days 0 and 21 and from whom assay results for antibodies against A/California-like HA antigen for blood samples taken were available.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK2340274A F1_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 64 y | 8.1 Fold increase |
| GSK2340274A F1_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 60 y | 8.4 Fold increase |
| GSK2340274A F1_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-60 y | 17.2 Fold increase |
| GSK2340274A F1_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-64 y | 16.6 Fold increase |
| GSK2340274A F2_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-60 y | 12.7 Fold increase |
| GSK2340274A F2_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 60 y | 5.8 Fold increase |
| GSK2340274A F2_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-64 y | 11.7 Fold increase |
| GSK2340274A F2_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 64 y | 5.8 Fold increase |
| GSK2340274A F2_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-64 y | 5.9 Fold increase |
| GSK2340274A F2_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 60 y | 2.8 Fold increase |
| GSK2340274A F2_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 64 y | 2.9 Fold increase |
| GSK2340274A F2_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-60 y | 6.8 Fold increase |
| GSK2340274A F1_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 64 y | 4.1 Fold increase |
| GSK2340274A F1_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 60 y | 4.2 Fold increase |
| GSK2340274A F1_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-60 y | 11.1 Fold increase |
| GSK2340274A F1_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-64 y | 10.6 Fold increase |
| GSK2340273A F1_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-60 y | 6.1 Fold increase |
| GSK2340273A F1_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 60 y | 3.5 Fold increase |
| GSK2340273A F1_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 64 y | 3.3 Fold increase |
| GSK2340273A F1_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-64 y | 6.3 Fold increase |
| GSK2340273A F2_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 64 y | 3.3 Fold increase |
| GSK2340273A F2_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-60 y | 9.0 Fold increase |
| GSK2340273A F2_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 60 y | 3.5 Fold increase |
| GSK2340273A F2_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-64 y | 9.3 Fold increase |
| GSK2340273A F2_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-64 y | 12.4 Fold increase |
| GSK2340273A F2_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 64 y | 2.7 Fold increase |
| GSK2340273A F2_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 60 y | 2.9 Fold increase |
| GSK2340273A F2_1D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-60 y | 12.3 Fold increase |
| GSK2340273A F3_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 64 y | 2.7 Fold increase |
| GSK2340273A F3_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, > 60 y | 2.8 Fold increase |
| GSK2340273A F3_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-64 y | 6.1 Fold increase |
| GSK2340273A F3_2D Group | Seroconversion Factor (SCF) for HI Antibodies Against A/California Virus Strain | A/California strain, 18-60 y | 6.4 Fold increase |
Secondary
Titers for HI Antibodies Against A/California Strain
Antibody titers were presented as geometric mean titers (GMTs), for the seropositivity cut-off of 1:10. Results were tabulated according to age strata: subjects between 18 to 60 years (y) old and \> 60 years and subjects between 18 and 64 years old and \> 64 years, respectively.
Time frame: At Days 0 and 21
Population: The analysis was performed on the ATP cohort for immunogenicity, which included all subjects who received the vaccine/ placebo doses on both Days 0 and 21 and from whom assay results for antibodies against A/California-like HA antigen for blood samples taken were available.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK2340274A F1_2D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (18-60 y), Day 21 | 415.0 Titers |
| GSK2340274A F1_2D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (18-64 y), Day 21 | 389.2 Titers |
| GSK2340274A F1_2D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (>60 y), Day 0 | 12.8 Titers |
| GSK2340274A F1_2D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (18-60 y), Day 0 | 13.9 Titers |
| GSK2340274A F1_2D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (>64 y), Day 0 | 13.0 Titers |
| GSK2340274A F1_2D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (>60 y), Day 21 | 150.7 Titers |
| GSK2340274A F1_2D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (18-64 y), Day 0 | 13.5 Titers |
| GSK2340274A F1_2D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (>64 y), Day 21 | 143.5 Titers |
| GSK2340274A F2_2D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (18-64 y), Day 0 | 14.5 Titers |
| GSK2340274A F2_2D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (18-60 y), Day 21 | 299.1 Titers |
| GSK2340274A F2_2D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (18-64 y), Day 21 | 265.2 Titers |
| GSK2340274A F2_2D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (>60 y), Day 0 | 10.2 Titers |
| GSK2340274A F2_2D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (18-60 y), Day 0 | 14.9 Titers |
| GSK2340274A F2_2D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (>64 y), Day 21 | 83.0 Titers |
| GSK2340274A F2_2D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (>64 y), Day 0 | 10.1 Titers |
| GSK2340274A F2_2D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (>60 y), Day 21 | 84.1 Titers |
| GSK2340274A F2_1D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (>64 y), Day 21 | 90.7 Titers |
| GSK2340274A F2_1D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (18-60 y), Day 0 | 11.3 Titers |
| GSK2340274A F2_1D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (>60 y), Day 21 | 88.9 Titers |
| GSK2340274A F2_1D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (18-64 y), Day 0 | 10.9 Titers |
| GSK2340274A F2_1D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (18-64 y), Day 21 | 172.1 Titers |
| GSK2340274A F2_1D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (18-60 y), Day 21 | 191.7 Titers |
| GSK2340274A F2_1D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (>60 y), Day 0 | 13.4 Titers |
| GSK2340274A F2_1D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (>64 y), Day 0 | 13.9 Titers |
| GSK2340274A F1_1D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (>64 y), Day 21 | 118.8 Titers |
| GSK2340274A F1_1D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (>64 y), Day 0 | 12.4 Titers |
| GSK2340274A F1_1D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (18-64 y), Day 0 | 12.1 Titers |
| GSK2340274A F1_1D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (>60 y), Day 21 | 118.5 Titers |
| GSK2340274A F1_1D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (>60 y), Day 0 | 11.9 Titers |
| GSK2340274A F1_1D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (18-60 y), Day 0 | 12.9 Titers |
| GSK2340274A F1_1D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (18-64 y), Day 21 | 359.6 Titers |
| GSK2340274A F1_1D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (18-60 y), Day 21 | 391.0 Titers |
| GSK2340273A F1_1D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (18-60 y), Day 0 | 15.0 Titers |
| GSK2340273A F1_1D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (18-60 y), Day 21 | 149.9 Titers |
| GSK2340273A F1_1D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (>60 y), Day 21 | 72.6 Titers |
| GSK2340273A F1_1D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (18-64 y), Day 0 | 14.5 Titers |
| GSK2340273A F1_1D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (>60 y), Day 0 | 11.9 Titers |
| GSK2340273A F1_1D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (18-64 y), Day 21 | 149.1 Titers |
| GSK2340273A F1_1D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (>64 y), Day 0 | 12.1 Titers |
| GSK2340273A F1_1D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (>64 y), Day 21 | 69.3 Titers |
| GSK2340273A F2_2D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (18-60 y), Day 0 | 10.6 Titers |
| GSK2340273A F2_2D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (>64 y), Day 21 | 42.2 Titers |
| GSK2340273A F2_2D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (>60 y), Day 21 | 47.0 Titers |
| GSK2340273A F2_2D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (18-64 y), Day 0 | 11.2 Titers |
| GSK2340273A F2_2D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (18-64 y), Day 21 | 183.1 Titers |
| GSK2340273A F2_2D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (>64 y), Day 0 | 9.4 Titers |
| GSK2340273A F2_2D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (18-60 y), Day 21 | 167.6 Titers |
| GSK2340273A F2_2D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (>60 y), Day 0 | 9.9 Titers |
| GSK2340273A F2_1D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (18-60 y), Day 0 | 11.0 Titers |
| GSK2340273A F2_1D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (18-64 y), Day 21 | 234.9 Titers |
| GSK2340273A F2_1D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (18-64 y), Day 0 | 11.3 Titers |
| GSK2340273A F2_1D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (>64 y), Day 0 | 12.2 Titers |
| GSK2340273A F2_1D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (>60 y), Day 0 | 12.4 Titers |
| GSK2340273A F2_1D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (>60 y), Day 21 | 47.6 Titers |
| GSK2340273A F2_1D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (>64 y), Day 21 | 42.7 Titers |
| GSK2340273A F2_1D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (18-60 y), Day 21 | 231.9 Titers |
| GSK2340273A F3_2D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (>60 y), Day 21 | 47.3 Titers |
| GSK2340273A F3_2D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (>64 y), Day 0 | 12.6 Titers |
| GSK2340273A F3_2D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (18-60 y), Day 21 | 100.3 Titers |
| GSK2340273A F3_2D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (>64 y), Day 21 | 46.0 Titers |
| GSK2340273A F3_2D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (18-64 y), Day 21 | 96.6 Titers |
| GSK2340273A F3_2D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (18-60 y), Day 0 | 11.0 Titers |
| GSK2340273A F3_2D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (18-64 y), Day 0 | 10.8 Titers |
| GSK2340273A F3_2D Group | Titers for HI Antibodies Against A/California Strain | A/California strain (>60 y), Day 0 | 12.3 Titers |
Secondary
Titers for HI Antibodies Against the A/California Virus Strain
Antibody titers were presented as geometric mean titers (GMTs), for the seropositivity cut-off of 1:10. Results were tabulated according to age strata: subjects between 18 to 60 years (y) old and \> 60 years and subjects between 18 and 64 years old and \> 64 years, respectively.
Time frame: At Days 0 and 42
Population: The analysis was performed on the ATP cohort for immunogenicity, which included all subjects who received the vaccine/ placebo doses on both Days 0 and 21 and from whom assay results for antibodies against A/California-like HA antigen for blood samples taken were available.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK2340274A F1_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 42 | 243.7 Titers |
| GSK2340274A F1_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 42 | 235.1 Titers |
| GSK2340274A F1_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 0 | 11.3 Titers |
| GSK2340274A F1_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 42 | 503.9 Titers |
| GSK2340274A F1_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 42 | 565.0 Titers |
| GSK2340274A F1_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 0 | 14.2 Titers |
| GSK2340274A F1_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 0 | 11.2 Titers |
| GSK2340274A F1_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 0 | 14.8 Titers |
| GSK2340274A F2_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 0 | 10.2 Titers |
| GSK2340274A F2_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 0 | 14.3 Titers |
| GSK2340274A F2_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 42 | 146.1 Titers |
| GSK2340274A F2_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 0 | 13.9 Titers |
| GSK2340274A F2_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 0 | 10.3 Titers |
| GSK2340274A F2_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 42 | 468.9 Titers |
| GSK2340274A F2_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 42 | 424.9 Titers |
| GSK2340274A F2_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 42 | 142.7 Titers |
| GSK2340274A F2_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 0 | 13.4 Titers |
| GSK2340274A F2_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 0 | 10.9 Titers |
| GSK2340274A F2_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 0 | 13.9 Titers |
| GSK2340274A F2_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 42 | 139.2 Titers |
| GSK2340274A F2_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 0 | 10.5 Titers |
| GSK2340274A F2_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 42 | 79.1 Titers |
| GSK2340274A F2_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 42 | 76.8 Titers |
| GSK2340274A F2_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 42 | 125.0 Titers |
| GSK2340274A F1_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 42 | 114.4 Titers |
| GSK2340274A F1_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 0 | 14.3 Titers |
| GSK2340274A F1_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 42 | 301.1 Titers |
| GSK2340274A F1_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 0 | 13.5 Titers |
| GSK2340274A F1_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 42 | 108.6 Titers |
| GSK2340274A F1_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 0 | 12.3 Titers |
| GSK2340274A F1_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 42 | 254.6 Titers |
| GSK2340274A F1_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 0 | 13.4 Titers |
| GSK2340273A F1_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 42 | 97.6 Titers |
| GSK2340273A F1_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 0 | 15.2 Titers |
| GSK2340273A F1_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 0 | 15.0 Titers |
| GSK2340273A F1_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 0 | 10.7 Titers |
| GSK2340273A F1_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 42 | 64.8 Titers |
| GSK2340273A F1_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 42 | 65.1 Titers |
| GSK2340273A F1_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 42 | 99.9 Titers |
| GSK2340273A F1_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 0 | 10.8 Titers |
| GSK2340273A F2_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 0 | 10.0 Titers |
| GSK2340273A F2_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 42 | 197.4 Titers |
| GSK2340273A F2_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 0 | 11.2 Titers |
| GSK2340273A F2_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 42 | 50.5 Titers |
| GSK2340273A F2_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 0 | 10.6 Titers |
| GSK2340273A F2_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 0 | 9.5 Titers |
| GSK2340273A F2_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 42 | 214.5 Titers |
| GSK2340273A F2_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 42 | 55.9 Titers |
| GSK2340273A F2_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 0 | 11.0 Titers |
| GSK2340273A F2_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 42 | 36.6 Titers |
| GSK2340273A F2_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 42 | 203.8 Titers |
| GSK2340273A F2_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 0 | 12.9 Titers |
| GSK2340273A F2_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 42 | 41.8 Titers |
| GSK2340273A F2_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 0 | 11.3 Titers |
| GSK2340273A F2_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 42 | 210.2 Titers |
| GSK2340273A F2_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 0 | 12.8 Titers |
| GSK2340273A F3_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 0 | 11.6 Titers |
| GSK2340273A F3_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 42 | 81.9 Titers |
| GSK2340273A F3_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 0 | 9.4 Titers |
| GSK2340273A F3_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 42 | 58.2 Titers |
| GSK2340273A F3_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (> 60 y), Day 0 | 11.4 Titers |
| GSK2340273A F3_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 42 | 84.3 Titers |
| GSK2340273A F3_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 0 | 9.5 Titers |
| GSK2340273A F3_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (> 64 y), Day 42 | 58.0 Titers |
Secondary
Titers for HI Antibodies Against the A/California Virus Strain
Antibody titers were presented as geometric mean titers (GMTs), for the seropositivity cut-off of 1:10. Results were tabulated according to age strata: subjects between 18 to 60 years (y) old and \> 60 years and subjects between 18 and 64 years old and \> 64 years, respectively.
Time frame: At Days 0 and 182
Population: The analysis was performed on the ATP cohort for immunogenicity, which included all subjects who received the vaccine/ placebo doses on both Days 0 and 21 and from whom assay results for antibodies against A/California-like HA antigen for blood samples taken were available.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK2340274A F1_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (>60 y), Day 182 | 106.6 Titers |
| GSK2340274A F1_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (>60 y), Day 0 | 12.6 Titers |
| GSK2340274A F1_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (>64 y), Day 0 | 12.8 Titers |
| GSK2340274A F1_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 182 | 232.7 Titers |
| GSK2340274A F1_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (>64 y), Day 182 | 103.3 Titers |
| GSK2340274A F1_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 0 | 14.5 Titers |
| GSK2340274A F1_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 0 | 14.0 Titers |
| GSK2340274A F1_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 182 | 250.3 Titers |
| GSK2340274A F2_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 182 | 184.1 Titers |
| GSK2340274A F2_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 182 | 166.0 Titers |
| GSK2340274A F2_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (>64 y), Day 182 | 58.5 Titers |
| GSK2340274A F2_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 0 | 14.1 Titers |
| GSK2340274A F2_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (>60 y), Day 182 | 59.2 Titers |
| GSK2340274A F2_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (>60 y), Day 0 | 10.3 Titers |
| GSK2340274A F2_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (>64 y), Day 0 | 10.2 Titers |
| GSK2340274A F2_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 0 | 14.5 Titers |
| GSK2340274A F2_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (>64 y), Day 0 | 14.1 Titers |
| GSK2340274A F2_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 0 | 11.1 Titers |
| GSK2340274A F2_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (>60 y), Day 0 | 13.5 Titers |
| GSK2340274A F2_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 0 | 11.5 Titers |
| GSK2340274A F2_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (>60 y), Day 182 | 37.9 Titers |
| GSK2340274A F2_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 182 | 77.9 Titers |
| GSK2340274A F2_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 182 | 65.7 Titers |
| GSK2340274A F2_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (>64 y), Day 182 | 40.6 Titers |
| GSK2340274A F1_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 182 | 149.2 Titers |
| GSK2340274A F1_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (>60 y), Day 0 | 11.9 Titers |
| GSK2340274A F1_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (>64 y), Day 182 | 51.1 Titers |
| GSK2340274A F1_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 0 | 12.5 Titers |
| GSK2340274A F1_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 0 | 13.4 Titers |
| GSK2340274A F1_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (>64 y), Day 0 | 12.4 Titers |
| GSK2340274A F1_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 182 | 132.3 Titers |
| GSK2340274A F1_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (>60 y), Day 182 | 49.7 Titers |
| GSK2340273A F1_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (>64 y), Day 182 | 40.5 Titers |
| GSK2340273A F1_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 182 | 90.7 Titers |
| GSK2340273A F1_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 0 | 15.1 Titers |
| GSK2340273A F1_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 182 | 92.1 Titers |
| GSK2340273A F1_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (>60 y), Day 0 | 12.1 Titers |
| GSK2340273A F1_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (>60 y), Day 182 | 42.5 Titers |
| GSK2340273A F1_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 0 | 14.5 Titers |
| GSK2340273A F1_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (>64 y), Day 0 | 12.2 Titers |
| GSK2340273A F2_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (>64 y), Day 182 | 31.8 Titers |
| GSK2340273A F2_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (>64 y), Day 0 | 9.5 Titers |
| GSK2340273A F2_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (>60 y), Day 0 | 10.0 Titers |
| GSK2340273A F2_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 0 | 10.9 Titers |
| GSK2340273A F2_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 182 | 92.4 Titers |
| GSK2340273A F2_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (>60 y), Day 182 | 34.9 Titers |
| GSK2340273A F2_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 0 | 10.2 Titers |
| GSK2340273A F2_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 182 | 100.7 Titers |
| GSK2340273A F2_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (>60 y), Day 0 | 13.2 Titers |
| GSK2340273A F2_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 182 | 133.3 Titers |
| GSK2340273A F2_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 0 | 10.8 Titers |
| GSK2340273A F2_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (>64 y), Day 182 | 34.5 Titers |
| GSK2340273A F2_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 0 | 11.2 Titers |
| GSK2340273A F2_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (>64 y), Day 0 | 13.0 Titers |
| GSK2340273A F2_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 182 | 138.8 Titers |
| GSK2340273A F2_1D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (>60 y), Day 182 | 38.7 Titers |
| GSK2340273A F3_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 0 | 10.4 Titers |
| GSK2340273A F3_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 182 | 63.0 Titers |
| GSK2340273A F3_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (>64 y), Day 182 | 33.9 Titers |
| GSK2340273A F3_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (>60 y), Day 182 | 34.2 Titers |
| GSK2340273A F3_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-60 y), Day 182 | 66.6 Titers |
| GSK2340273A F3_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (18-64 y), Day 0 | 10.3 Titers |
| GSK2340273A F3_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (>60 y), Day 0 | 12.1 Titers |
| GSK2340273A F3_2D Group | Titers for HI Antibodies Against the A/California Virus Strain | A/California strain (>64 y), Day 0 | 12.3 Titers |